



Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma

Medicine - Oncology

 NIH Biosketch available Online

CLINICAL OFFICES

- **Lymphoma Clinic**

875 Blake Wilbur Dr Clinic C

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 725-9113

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Administrative Associate

Tel 650-725-6456

Bio

BIO

Ranjana H. Advani, MD is the Saul Rosenberg Professor of Lymphoma and serves as the Physician Leader of the Lymphoma Clinical Care Program. She specializes in research and treatment of Hodgkin and non-Hodgkin lymphomas and has developed a broad collaborative investigative program, encompassing clinical trials and translational correlates. She is the Principle Investigator on numerous clinical trials. She currently serves on the National Comprehensive Cancer Network (NCCN) non Hodgkin and Hodgkin Lymphoma (vice chair) guidelines panel, Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG) and the National Cancer Institute Lymphoma Steering Committee.

CLINICAL FOCUS

- Cancer > Lymphoma
- Burkitt's Lymphoma
- Hodgkin's Disease
- Investigational Therapeutics
- Lymphoma
- Mycosis Fungoides
- Non-Hodgkin's Lymphoma
- Oncology (Cancer)
- Plasmacytoma
- Waldenstrom's Macroglobulinemia
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Lymphoma DMG leader, Stanford Cancer Institute, (2010- present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (1996) CA
- Residency: Stanford University Internal Medicine Residency (1990) CA
- Internship: Santa Clara Valley Medical Center Internal Medicine Residency (1987) CA

- Board Certification: Medical Oncology, American Board of Internal Medicine (1995)
- Medical Education: Bombay University (1982) India

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

CLINICAL TRIALS

- A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors, Recruiting
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma, Recruiting
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma, Recruiting
- Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type, Recruiting
- Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma, Recruiting
- Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies, Recruiting
- Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma, Recruiting
- A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma, Not Recruiting
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6, Not Recruiting
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies, Not Recruiting
- Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma, Not Recruiting
- Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma, Not Recruiting
- Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma, Not Recruiting
- Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma, Not Recruiting
- Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma, Not Recruiting
- Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma, Not Recruiting
- Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma, Not Recruiting
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas, Not Recruiting
- Efficacy of Axicabtagene Ciloleucef Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
- FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma, Not Recruiting
- Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP), Not Recruiting
- Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy., Not Recruiting
- Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma, Not Recruiting
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma, Not Recruiting

- PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma, Not Recruiting
- Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia, Not Recruiting
- Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Not Recruiting
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma, Not Recruiting
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma, Not Recruiting
- Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma, Not Recruiting
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma, Not Recruiting
- S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma, Not Recruiting
- Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL), Not Recruiting
- Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy., Not Recruiting
- Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia, Not Recruiting
- Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors, Not Recruiting
- Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers, Not Recruiting
- Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma, Not Recruiting
- Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia, Not Recruiting
- Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma, Not Recruiting
- T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma, Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma** *CLINICAL CANCER RESEARCH*
Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R., Connors, J. M., Feldman, T., Forero-Torres, A., Friedberg, J. W., Gopal, A. K., Gordon, L. I., Kuruvilla, J., Savage, et al
2019; 25 (6): 1718–26
- **Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial** *LANCET*
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W., Feldman, et al
2019; 393 (10168): 229–40
- **Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma** *BRITISH JOURNAL OF HAEMATOLOGY*
Spinner, M. A., Varma, G., Advani, R. H.
2019; 184 (1): 17–29
- **Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.** *Lancet (London, England)*
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, et al

2018

- **CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., Thu Tran, Lynn, J., Chen, J. Y., et al
2018; 379 (18): 1711–21
- **Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Evens, A. M., Advani, R. H., Helenowski, I. B., Fanale, M., Smith, S. M., Jovanovic, B. D., Bociek, G. R., Klein, A. K., Winter, J. N., Gordon, L. I., Hamlin, P. A.
2018; 36 (30): 3015–+
- **Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Evens, A. M., Advani, R. H., Helenowski, I. B., Fanale, M., Smith, S. M., Jovanovic, B. D., Bociek, G. R., Klein, A. K., Winter, J. N., Gordon, L. I., Hamlin, P. A.
2018; JCO2018790139
- **End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making** *HAEMATOLOGICA*
Melani, C., Advani, R., Roschewski, M., Walters, K. M., Chen, C. C., Baratto, L., Ahlman, M. A., Miljkovic, M. D., Steinberg, S. M., Lam, J., Shovlin, M., Dunleavy, K., Pittaluga, et al
2018; 103 (8): 1337–44
- **Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma** *BLOOD*
LaCasce, A. S., Bociek, R., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, et al
2018; 132 (1): 40–48
- **The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project** *HAEMATOLOGICA*
Bellei, M., Foss, F. M., Shustov, A. R., Horwitz, S. M., Marcheselli, L., Kim, W., Cabrera, M. E., Dlouhy, I., Nagler, A., Advani, R. H., Pesce, E. A., Ko, Y., Martinez, et al
2018; 103 (7): 1191–97
- **Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network** *BRITISH JOURNAL OF HAEMATOLOGY*
Federico, M., Bellei, M., Marcheselli, L., Schwartz, M., Manni, M., Tarantino, V., Pileri, S., Ko, Y., Cabrera, M. E., Horwitz, S., Kim, W. S., Shustov, A., Foss, et al
2018; 181 (6): 760–69
- **Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.**
Advani, R. H., Flinn, I., Popplewell, L., Forero-Torres, A., Bartlett, N. L., Ghosh, N., Kline, J., Tran, T., Lynn, J., Chen, J. Y., Agoram, B., Huang, J., Takimoto, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma** *BLOOD*
Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Ansell, S. M., Moskowitz, C. H., Fenton, K., Ogden, C., Taft, D., Zhang, et al
2018; 131 (11): 1183–94
- **Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.** *Blood advances*
Spinner, M. A., Advani, R. H., Hoppe, R. T., Lowsky, R., Muffly, L. S.
2018; 2 (13): 1547–50
- **CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.** *The New England journal of medicine*
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., Tran, T., Lynn, J., Chen, et al
2018; 379 (18): 1711–21
- **PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.** *Journal of clinical oncology*
Roemer, M. G., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., Armand, P., Chapuy, B., De Jong, et al

2016; 34 (23): 2690-2697

- **A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis** *LANCET ONCOLOGY*
Kim, S. J., Yoon, D. H., Jaccard, A., Chng, W. J., Lim, S. T., Hong, H., Park, Y., Chang, K. M., Maeda, Y., Ishida, F., Shin, D., Kim, J. S., Jeong, et al
2016; 17 (3): 389-400
- **A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.** *British journal of haematology*
Advani, R. H., Ansell, S. M., Lechowicz, M. J., Beaven, A. W., Loberiza, F., Carson, K. R., Evens, A. M., Foss, F., Horwitz, S., Pro, B., Pinter-Brown, L. C., Smith, S. M., Shustov, et al
2016; 172 (4): 535-544
- **Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era** *BRITISH JOURNAL OF HAEMATOLOGY*
Diefenbach, C. S., Li, H., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Crump, M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Kahl, et al
2015; 171 (4): 530-538
- **Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.** *Current treatment options in oncology*
Iberri, D. J., Hoppe, R. T., Advani, R. H.
2015; 16 (9): 45-?
- **Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)** *BRITISH JOURNAL OF HAEMATOLOGY*
Swinnen, L. J., Li, H., Quon, A., Gascoyne, R., Hong, F., Ranheim, E. A., Habermann, T. M., Kahl, B. S., Horning, S. J., Advani, R. H.
2015; 170 (1): 56-65
- **Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.** *Journal of clinical oncology*
Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Gordon, L. I., Kahl, B. S., Friedberg, et al
2015; 33 (17): 1936-1942
- **Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial** *JOURNAL OF CLINICAL ONCOLOGY*
Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Gordon, L. I., Kahl, B. S., Friedberg, et al
2015; 33 (17): 1936-U111
- **Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia** *NEW ENGLAND JOURNAL OF MEDICINE*
Trean, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., Patterson, C. J., Rodig, S., Zehnder, et al
2015; 372 (15): 1430-1440
- **Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).** *Leukemia & lymphoma*
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., Habermann, T. M., Kahl, B. S., Advani, R. H.
2014; 55 (4): 768-772
- **Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.** *Journal of clinical oncology*
Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., Bartlett, N. L.
2014; 32 (9): 912-918
- **Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.** *Journal of clinical oncology*
Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., Bartlett, N. L.
2014; 32 (9): 912-918
- **Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).** *Blood*
Chang, J. E., Li, H., Smith, M. R., Gascoyne, R. D., Palletta, E. M., Yang, D. T., Advani, R. H., Horning, S. J., Kahl, B. S.
2014; 123 (11): 1665-1673

- **How I treat nodular lymphocyte predominant Hodgkin lymphoma** *BLOOD*
Advani, R. H., Hoppe, R. T.
2013; 122 (26): 4182-4188
- **Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.** *Blood*
Tan, D., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., Warnke, R. A., Natkunam, Y., Han, S. S., Yuen, A., Plevritis, S. K., Advani, R. H.
2013; 122 (6): 981-987
- **Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, et al
2013; 369 (6): 507-516
- **Targeted Therapy in Relapsed Classical Hodgkin Lymphoma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Dinner, S., Advani, R.
2013; 11 (8): 968-976
- **Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.** *Blood*
Kanakry, J. A., Li, H., Gellert, L. L., Lemas, M. V., Hsieh, W., Hong, F., Tan, K. L., Gascoyne, R. D., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Stiff, P., Cheson, et al
2013; 121 (18): 3547-3553
- **Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., Staudt, L. M., Jaffe, E. S., Wilson, et al
2013; 368 (15): 1408-1416
- **Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial** *ANNALS OF ONCOLOGY*
Advani, R. H., Hoppe, R. T., Baer, D., Mason, J., Warnke, R., Allen, J., Daadi, S., Rosenberg, S. A., Horning, S. J.
2013; 24 (4): 1044-1048
- **The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496** *BRITISH JOURNAL OF HAEMATOLOGY*
Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Gospodarowicz, M., Cheson, B. D., Stiff, P. J., Advani, R., Miller, et al
2013; 161 (1): 76-86
- **Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)** *JOURNAL OF CLINICAL ONCOLOGY*
Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Gospodarowicz, M., Advani, R., Kahl, B. S., Friedberg, et al
2013; 31 (6): 684-691
- **Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials** *JOURNAL OF CLINICAL ONCOLOGY*
Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., Advani, R. H.
2013; 31 (5): 592-598
- **Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma** *BLOOD*
Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., Krouwer, H., Hwang, J., Auerback, G., Kadoch, C., Lowell, C., Munster, et al
2013; 121 (5): 745-751
- **Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies** *JOURNAL OF CLINICAL ONCOLOGY*
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., Sukbuntherng, J., Izumi, R., Hamdy, et al
2013; 31 (1): 88-94

- **Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial** *BLOOD*
Tan, K. L., Scott, D. W., Hong, F., Kahl, B. S., Fisher, R. I., Bartlett, N. L., Advani, R. H., Buckstein, R., Rimsza, L. M., Connors, J. M., Steidl, C., Gordon, L. I., Horning, et al
2012; 120 (16): 3280-3287
- **Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499** *JOURNAL OF CLINICAL ONCOLOGY*
Smith, M. R., Li, H., Gordon, L., Gascoyne, R. D., Paietta, E., Forero-Torres, A., Kahl, B. S., Advani, R., Hong, F., Horning, S. J.
2012; 30 (25): 3119-3126
- **Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies** *ONCOLOGIST*
Forero-Torres, A., Fanale, M., Advani, R., Bartlett, N. L., Rosenblatt, J. D., Kennedy, D. A., Younes, A.
2012; 17 (8): 1073-1080
- **Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study** *JOURNAL OF CLINICAL ONCOLOGY*
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, et al
2012; 30 (18): 2190-2196
- **Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial** *LEUKEMIA & LYMPHOMA*
Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., Habermann, T. M., Ganjoo, K.
2012; 53 (4): 718-720
- **STAGE I-III A NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., Horning, S. J.
2011; 81 (5): 1374-1379
- **MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP** *CLINICAL CANCER RESEARCH*
Alencar, A. J., Malumbres, R., Kozloski, G. A., Advani, R., Talreja, N., Chinichian, S., Briones, J., Natkunam, Y., Sehn, L. H., Gascoyne, R. D., Tibshirani, R., Lossos, I. S.
2011; 17 (12): 4125-4135
- **Current concepts and controversies in the management of early stage Hodgkin lymphoma** *LEUKEMIA & LYMPHOMA*
Maeda, L. S., Lee, M., Advani, R. H.
2011; 52 (6): 962-971
- **Optimal therapy of advanced Hodgkin lymphoma.** *Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program*
Advani, R.
2011; 2011: 310-316
- **Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI)** *48th Annual Meeting of the American-Society-of-Hematology*
Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. A., Fisher, R. I., Peterson, B. A., Gascoyne, R. D., Horning, S. J.
WILEY-BLACKWELL PUBLISHING, INC.2010: 143-51
- **Risk stratification in extranodal natural killer/T-cell lymphoma** *EXPERT REVIEW OF ANTICANCER THERAPY*
Kohrt, H., Lee, M., Advani, R.
2010; 10 (9): 1395-1405
- **Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Talreja, N., Shyam, R., Natkunam, Y., Gascoyne, R. D., Briones, J., Advani, R., Lossos, I. S., Levy, et al
AMER SOC HEMATOLOGY.2009: 258-58
- **Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*

- Advani, R. H., Hoppe, R. T., Baer, D. M., Mason, J., Rosenberg, S. A., Horning, S. J.
AMER SOC HEMATOLOGY.2009: 666–67
- **Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009** *LANCET ONCOLOGY*
Kwong, Y., Anderson, B. O., Advani, R., Kim, W., Levine, A. M., Lim, S.
2009; 10 (11): 1093-1101
 - **Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma** *10th International Conference on Malignant Lymphoma*
Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., Harrop, K., Whiting, N., Drachman, J. G.
AMER SOC CLINICAL ONCOLOGY.2009: 4371–77
 - **Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease** *9th International Conference on Malignant Lymphoma*
Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., Rosenberg, S. A., Horning, S. J.
AMER SOC CLINICAL ONCOLOGY.2007: 3902–7
 - **Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine** *LEUKEMIA & LYMPHOMA*
Advani, R., Horwitz, S., Zelenetz, A., Horning, S. J.
2007; 48 (3): 521-525
 - **Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy** *8th International Conference on Malignant Lymphoma*
Advani, R., Rosenberg, S. A., Horning, S. J.
AMER SOC CLINICAL ONCOLOGY.2004: 1454–59
 - **Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.** *The Lancet. Haematology*
Cheson, B. D., Bartlett, N. L., LaPlant, B., Lee, H. J., Advani, R. J., Christian, B., Diefenbach, C. S., Feldman, T. A., Ansell, S. M.
2020
 - **Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial** *LANCET HAEMATOLOGY*
Diefenbach, C. S., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., David, K. A., Advani, R. H., Fenske, T. S., Barta, S. K., Palmisiano, N. D., Svoboda, J., Morgan, D. S., Karmali, et al
2020; 7 (9): E660–E670
 - **Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.** *The Lancet. Haematology*
Diefenbach, C. S., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., David, K. A., Advani, R. H., Fenske, T. S., Barta, S. K., Palmisiano, N. D., Svoboda, J., Morgan, D. S., Karmali, et al
2020; 7 (9): e660–e670
 - **Angioimmunoblastic T-Cell Lymphoma: Report on 282 Cases from the Prospective International T-Cell Lymphoma Project**
Skrypets, T., Civallero, M., Manni, M., Pileri, S., Weisenburger, D. D., Ko, Y., Inghirami, G., Bargetzi, M., Gabus, R., Bobillo Varela, S., Horwitz, S. M., Pavlovsky, A., Thieblemont, et al
CIG MEDIA GROUP, LP.2020: S253–S254
 - **Consensus Statement on the Management of Waldenstrom Macroglobulinemia Patients During the COVID-19 Pandemic.** *HemaSphere*
Talaouikar, D., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., Kersten, M. J., Leblond, V., Minnema, M. C., Owen, R. G., Palomba, M. L., Tedeschi, A., Trotman, et al
2020; 4 (4): e433
 - **A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Evens, A. M., Hong, F., Habermann, T. M., Advani, R. H., Gascoyne, R. D., Witzig, T. E., Quon, A., Ranheim, E. A., Ansell, S. M., Cheema, P. S., Dy, P. A., O'Brien, T. E., Winter, et al
2020
 - **Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation.** *Leukemia & lymphoma*
Weil, C. R., Qian, Y., Von Eyben, R., Daadi, S. E., Corbelli, K. S., Rosenberg, S. A., Advani, R. H., Hoppe, R. T.

2020: 1–7

- **Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of Academic and Community Cancer Research United (ACCRU) RU051505I.**
Cheson, B. D., Bartlett, N. L., LaPlant, B., Lee, H., Advani, R. H., Christian, B., Diefenbach, C., Feldman, T., Ansell, S. M.
AMER SOC CLINICAL ONCOLOGY.2020
- **Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium.**
Fu, K., Yu, G., Bi, C., Cheng, H., Smith, L., Yuan, J., Naushad, H., Link, B. K., Nichols, C. R., Barr, P. M., Kahl, B. S., Stewart, D., Barta, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study.** *JCO oncology practice*
Lynch, R. C., Sundaram, V., Desai, M., Henry, S., Wood, D., Daadi, S., Hoppe, R. T., Advani, R.
2020: JOP1900733
- **Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON-2 trial**
Illidge, T., Horwitz, S., Iyer, S., Bartlett, N., Kim, W. S., Belada, D., Feldman, T., Illes, A., Jacobsen, E., Huettmann, A., Zinzani, P. L., O'Connor, O., Mckay, et al
WILEY.2020: 111–12
- **Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study**
Radford, J., Bartlett, N., Straus, D., Dlugosz-Danecka, M., Alekseev, S., Illes, A., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K., Walewski, J., Ramchandren, R., Zinzani, et al
WILEY.2020: 101–2
- **The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.** *British journal of haematology*
Fowler, N. H., Nastoupil, L., De Vos, S., Knapp, M., Flinn, I. W., Chen, R., Advani, R. H., Bhatia, S., Martin, P., Mena, R., Davis, R. E., Neelapu, S. S., Eckert, et al
2020
- **POPULATION PHARMACOKINETICS OF MAGROLIMAB (5F9, HU5F9--G4) IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS.**
Agoram, B., Jin, C., Wang, B., Sikic, B., Advani, R., Chao, M., Takimoto, C.
WILEY.2020: S85
- **Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.** *British journal of haematology*
LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, et al
2020
- **Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.** *The Lancet. Haematology*
Castillo, J. J., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., Kersten, M. J., Leblond, V., Minnema, M. C., Owen, R. G., Palomba, M. L., Talaulikar, D., Tedeschi, et al
2020; 7 (11): e827–e837
- **Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Treon, S. P., Meid, K., Gustine, J., Yang, G., Xu, L., Liu, X., Patterson, C. J., Hunter, Z. R., Branagan, A. R., Laubach, J. P., Ghobrial, I. M., Palomba, M. L., Advani, et al
2020: JCO2000555
- **Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.** *Blood*
Straus, D. J., Dlugosz-Danecka, M., Alekseev, S., Illes, A., Picardi, M., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Ramchandren, R., Zinzani, et al
2020
- **Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.** *Blood advances*
Torka, P., Kothari, S. K., Sundaram, S., Li, S., Medeiros, L. J., Ayers, E. C., Landsburg, D. J., Bond, D. A., Maddocks, K. J., Giri, A., Hess, B., Pham, L. Q., Advani, et al
2020; 4 (2): 253–62

- **Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.** *British journal of haematology*
Carreau, N. A., Armand, P., Merryman, R. W., Advani, R. H., Spinner, M. A., Herrera, A. F., Ramchandren, R., Hamid, M. S., Assouline, S., Santiago, R., Wagner-Johnston, N., Paul, S., Svoboda, et al
2020
- **Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.** *The oncologist*
Merryman, R. W., Carreau, N. A., Advani, R. H., Spinner, M. A., Herrera, A. F., Chen, R., Tomassetti, S., Ramchandren, R., Hamid, M., Assouline, S., Santiago, R., Nina Wagner-Johnston, N., Paul, et al
2020
- **Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Armand, P., Bello, C. M., Benitez, C. M., Bierman, P. J., Boughan, K. M., Dabaja, B., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Herrera, et al
2020; 18 (6): 755–81
- **Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG.** *Blood*
Binkley, M. S., Rauf, M. S., Milgrom, S. A., Pinnix, C. C., Tsang, R. W., Dickinson, M., Ng, A., Roberts, K. B., Gao, S., Balogh, A. G., Ricardi, U., Levis, M., Casulo, et al
2020
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.** *Archives of pathology & laboratory medicine*
Menke, J. R., Spinner, M. A., Natkunam, Y., Warnke, R. A., Advani, R. H., Gratzinger, D. A.
2020
- **Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma.** *Blood*
Allen, P. B., Savas, H., Evens, A. M., Advani, R., Palmer, B., Pro, B., Karmali, R., Mou, E., Bearden, J., Dillehay, G., Bayer, R., Eisner, R. M., Chmiel, et al
2020
- **Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.** *The oncologist*
Carreau, N. A., Pail, O., Armand, P., Merryman, R., Advani, R. H., Herrera, A. F., Chen, R., Tomassetti, S., Ramchandren, R., Assouline, S., Santiago, R., Wagner-Johnston, N., Paul, et al
2020
- **T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.** *Blood advances*
Ghione, P., Faruque, P., Mehta-Shah, N., Seshan, V., Ozkaya, N., Bhaskar, S., Yeung, J., Spinner, M. A., Lunning, M., Inghirami, G., Moskowitz, A., Galasso, N., Ganesan, et al
2020; 4 (19): 4640–47
- **Incidence and Outcomes of Rare T cell Lymphomas from the T Cell Project: Hepatosplenic, Enteropathy Associated and Peripheral Gamma Delta T cell Lymphomas.** *American journal of hematology*
Foss, F. M., Horwitz, S. M., Civallero, M., Bellei, M., Marcheselli, L., Kim, W. S., Cabrera, M. E., Dlouhy, I., Nagler, A., Advani, R. H., Pesce, E. A., Ko, Y., Montoto, et al
2019
- **Updates in Treatment Strategies for Hodgkin Lymphoma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Advani, R. H.
2019; 17 (11): 1411–13
- **Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia**
Castillo, J., Allan, J., Siddiqi, T., Advani, R., Keezer, A., Gustine, J., Meid, K., Dubeau, T., Lam, J., Xu, L., Yang, G., Hunter, Z., Furman, et al
CIG MEDIA GROUP, LP.2019: E39–E40
- **Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

- Rosenwald, A., Bens, S., Advani, R., Barrans, S., Copie-Bergman, C., Elsensohn, M., Natkunam, Y., Calaminici, M., Sander, B., Baia, M., Smith, A., Painter, D., Pham, et al
2019: JCO1900743
- **Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.** *Acta haematologica*
Lansigan, F., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, M., Shustov, A. R., Advani, et al
2019: 1–11
 - **Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.** *Oncotarget*
Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., Augustson, B., Marlton, P., Commerford, S. R., Okrah, K., Liu, L., Murray, E., Penuel, et al
2019; 10 (38): 3827–30
 - **B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., Chang, J. E., Chavez, J. C., Christian, B., Fayad, L. E., Glenn, M. J., Habermann, T. M., Harris, et al
2019; 17 (6): 651–61
 - **Response to A+CHP by CD30 expression in the ECHELON-2 trial.**
Advani, R. H., Horwitz, S. M., Iyer, S., Bartlett, N. L., Kim, W., Tilly, H., Belada, D., Feldman, T., Illes, A., Jacobsen, E. D., Huettmann, A., Zinzani, P., O'Connor, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.**
Thanarajasingam, G., Dueck, A. C., Novotny, P. J., Habermann, T., Advani, R. H., Gascoyne, R. D., Witzig, T. E., Quon, A., Ranheim, E., Kahl, B. S., Evens, A. M., Hong, F.
AMER SOC CLINICAL ONCOLOGY.2019
 - **Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.**
Jagadeesh, D., Horwitz, S. M., Bartlett, N. L., Advani, R. H., Jacobsen, E. D., Duvic, M., Gautam, A., Rao, S., Onsum, M., Fanale, M., Kim, Y. H.
AMER SOC CLINICAL ONCOLOGY.2019
 - **Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)** *LANCET HAEMATOLOGY*
Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., Press, O. W., Salles, G., Tilly, H., Chen, A. I., Assouline, S., Cheson, B. D., Dreyling, et al
2019; 6 (5): E254–E265
 - **The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study** *CANCER*
Park, S. I., Horwitz, S. M., Foss, F. M., Pinter-Brown, L. C., Carson, K. R., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, et al
2019; 125 (9): 1507–17
 - **Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).** *The Lancet. Haematology*
Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., Press, O. W., Salles, G., Tilly, H., Chen, A. I., Assouline, S., Cheson, B. D., Dreyling, et al
2019
 - **Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019; 37 (9): 755–+
 - **CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features**
Menke, J., Spinner, M., Shrestha, B., Advani, R., Natkunam, Y., Gratzinger, D.
NATURE PUBLISHING GROUP.2019
 - **CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features**

Menke, J., Spinner, M., Shrestha, B., Advani, R., Natkunam, Y., Gratzinger, D.
NATURE PUBLISHING GROUP.2019

- **Reply to J. Wang et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019: JCO1801907
- **CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma REPLY** *NEW ENGLAND JOURNAL OF MEDICINE*
Advani, R., Volkmer, J., Chao, M. P.
2019; 380 (5): 497–98
- **The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.** *Cancer*
Park, S. I., Horwitz, S. M., Foss, F. M., Pinter-Brown, L. C., Carson, K. R., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, et al
2019
- **Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R., Connors, J. M., Feldman, T., Forero, A., Friedberg, J. W., Gopal, A. K., Gordon, L. I., Kuruvilla, J., Savage, et al
2019
- **CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.** *The New England journal of medicine*
Advani, R., Volkmer, J., Chao, M. P.
2019; 380 (5): 497–98
- **The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs)**
Truemper, L., O'Connor, O. A., Pro, B., Illidge, T. M., Advani, R. H., Bartlett, N. L., Christensen, H. J., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T. A., Lennard, et al
KARGER.2019: 23
- **Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy** *RADIO THERAPY AND ONCOLOGY*
Moding, E. J., Advani, R., Rosenberg, S. A., Hoppe, R. T.
2018; 129 (3): 507–12
- **Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*
Moding, E. J., Advani, R., Rosenberg, S. A., Hoppe, R. T.
2018; 129 (3): 507–12
- **Risk-adapted therapy for advanced-stage Hodgkin lymphoma.** *Hematology. American Society of Hematology. Education Program*
Spinner, M. A., Advani, R. H.
2018; 2018 (1): 200–206
- **Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenström Macroglobulinemia**
Castillo, J. J., Gustine, J., Meid, K., Dubeau, T., Keezer, A., Allan, J. N., Furman, R. R., Siddiqi, T., Advani, R., Lam, J., Hunter, Z. R., Yang, G., Xu, et al
AMER SOC HEMATOLOGY.2018
- **Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes**
Bannerji, R., Amason, J. E., Advani, R., Brown, J. R., Allan, J. N., Ansell, S. M., Barnes, J., O'Brien, S. M., Chavez, J. C., Duell, J., Lowy, I., Charnas, R., Sternberg, et al
AMER SOC HEMATOLOGY.2018
- **A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)**
Diefenbach, C., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M., David, K. A., Advani, R. H., Fenske, T. S., Barta, S., Palmisano, N., Svoboda, J., Morgan, D., Karmali, et al

AMER SOC HEMATOLOGY.2018

- **The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid (R) Continuation (BIONIC) Study**
Baratto, L., Jegede, O., Hong, F., Habermann, T. M., Advani, R., Gascoyne, R. D., Kostakoglu, L., Witzig, T. E., Ranheim, E. A., Kahl, B. S., Quon, A., Evens, A. M.
AMER SOC HEMATOLOGY.2018
- **Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers**
Kothari, S. K., Li, S., Medeiros, L., Ayers, E. C., Landsburg, D. J., Bond, D. A., Maddocks, K. J., Giri, A., Hess, B. T., Pham, L. Q., Advani, R., Liu, Y., Barta, et al
AMER SOC HEMATOLOGY.2018
- **Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)**
Advani, R. H., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Christian, B. A., Ansell, S. M., Moskowitz, C. H., Fenton, K., Ogden, C., Taft, et al
AMER SOC HEMATOLOGY.2018
- **A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis**
Savas, H., Allen, P., Evens, A. M., Pro, B., Dillehay, G., Rademaker, A., Palmer, B., Advani, R., Gordon, L. I., Winter, J. N.
AMER SOC HEMATOLOGY.2018
- **The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas**
Horwitz, S. M., O'Connor, O. A., Pro, B., Illidge, T. M., Fanale, M. A., Advani, R. H., Bartlett, N. L., Christensen, J., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W., Feldman, et al
AMER SOC HEMATOLOGY.2018
- **Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy**
Carreau, N. A., Pail, O., Armand, P., Merryman, R. W., Advani, R. H., Spinner, M. A., Herrera, A. F., Chen, R. W., Tomassetti, S., Ramchandren, R., Hamid, M., Assouline, S., Santiago, et al
AMER SOC HEMATOLOGY.2018
- **Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)**
Hong, F., Thanarajasingam, G., Ansell, S. M., Ambinder, R. F., Cohen, J. B., Robertson, M., David, K. A., Advani, R. H., Fenske, T. S., Barta, S., Palmisiano, N., Svoboda, J., Morgan, et al
AMER SOC HEMATOLOGY.2018
- **No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission**
Lynch, R. C., Sundaram, V., Desai, M., Henry, S., Wood, D., Daadi, S., Corbelli, K. S., Rosenberg, S., Hoppe, R. T., Advani, R.
AMER SOC HEMATOLOGY.2018
- **Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma**
Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., Sworder, B., Soo, J., Glover, C., Roschewski, M., Wilson, W. H., Duhrsen, U., Huettmann, et al
AMER SOC HEMATOLOGY.2018
- **Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing**
Schroers-Martin, J. G., Garofalo, A., Soo, J., Jin, M. C., Kurtz, D. M., Buedts, L., Duhrsen, U., Huettmann, A., Cottreau, A., Meignan, M., Casasnovas, O., Westin, J. R., Gaidano, et al
AMER SOC HEMATOLOGY.2018
- **A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408**
Hong, F., Evens, A. M., Novotny, P. J., Habermann, T. M., Advani, R. H., Gascoyne, R. D., Witzig, T. E., Quon, A., Ranheim, E. A., Dueck, A. C., Kahl, B. S., Thanarajasingam, G.
AMER SOC HEMATOLOGY.2018

- **Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.** *British journal of haematology*
Spinner, M. A., Varma, G., Advani, R. H.
2018
- **Risk-adapted therapy for advanced-stage Hodgkin lymphoma** *HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM*
Spinner, M. A., Advani, R. H.
2018: 200–206
- **Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiation Therapy**
Moding, E. J., Advani, R. H., Rosenberg, S. A., Hoppe, R. T.
ELSEVIER SCIENCE INC.2018: S189–S190
- **The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation**
Weil, C., Qian, Y., Von Eyben, R., Daadi, S. E., Corbelli, K. S., Rosenberg, S. A., Advani, R. H., Hoppe, R. T.
ELSEVIER SCIENCE INC.2018: S189
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. M., Esfahani, M., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018; 36 (28): 2845–+
- **Novel Approaches in Waldenstrom Macroglobulinemia** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Spinner, M. A., Varma, G., Advani, R. H.
2018; 32 (5): 875–+
- **Novel Approaches in Waldenstrom Macroglobulinemia.** *Hematology/oncology clinics of North America*
Spinner, M. A., Varma, G., Advani, R. H.
2018; 32 (5): 875–90
- **Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia** *HAEMATOLOGICA*
Castillo, J. J., Gustine, J. N., Meid, K., Dubeau, T. E., Xu, L., Yang, G., Hunter, Z. R., Advani, R., Palomba, L., Treon, S. P.
2018; 103 (10): E466–E468
- **Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation** *CLINICAL CANCER RESEARCH*
Aghighi, M., Theruvath, A. J., Pareek, A., Pisani, L. L., Alford, R., Muehe, A. M., Sethi, T. K., Holdsworth, S. J., Hazard, F. K., Gratzinger, D., Luna-Fineman, S., Advani, R., Spunt, et al
2018; 24 (17): 4110–18
- **Circulating tumor DNA (ctDNA) in B-cell lymphoma**
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Green, M. R., Liu, C. L., Zhou, L., Glover, et al
WILEY.2018: 16–17
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018: JCO2018785246
- **Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.**
Diefenbach, C., Hong, F., Ambinder, R. F., Cohen, J., David, K., Advani, R. H., Robertson, M. J., Fenske, T. S., Barta, S. K., Palmisano, N., Svoboda, J., Morgan, D. S., Karmali, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study.**
Evens, A. M., Advani, R. H., Fanale, M. A., Smith, S. M., Helenowski, I. B., Bociek, G., Klein, A., Winter, J. N., Gordon, L. I., Hamlin, P. A.
AMER SOC CLINICAL ONCOLOGY.2018
- **Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.**
Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R. W., Feldman, T., Forero-Torres, A., Friedberg, J. W., Gopal, A. K., Gordon, L. I., Kuruvilla, J., Savage, K. J., Straus, et al

AMER SOC CLINICAL ONCOLOGY.2018

- **Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas** *BLOOD*
Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., Chen, R. W., Davies, A., Illidge, T., Uttarwar, M., Lee, S., Ren, H., Kennedy, et al
2018; 131 (19): 2120–24
- **The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Constine, L. S., Yahalom, J., Ng, A. K., Hodgson, D. C., Wirth, A., Milgrom, S. A., Mikhaeel, N., Eich, H., Illidge, T., Ricardi, U., Dieckmann, K., Moskowitz, C. H., Advani, et al
2018; 100 (5): 1100–1118
- **NCCN Guidelines (R) Insights Hodgkin Lymphoma, Version 1.2018 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Armand, P., Bello, C. M., Benitez, C. M., Bierman, P. J., Chen, R., Dabaja, B., Dean, R., Forero, et al
2018; 16 (3): 245–54
- **First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.** *Oncotarget*
Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., Augustson, B., Marlton, P., Renee Commerford, S., Okrah, K., Liu, L., Murray, E., Penuel, et al
2018; 9 (16): 13023–35
- **Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)** *ONCOTARGET*
Swinnen, L. J., O'Neill, A., Imus, P. H., Gujar, S., Schiff, D., Kleinberg, L. R., Advani, R. H., Dunbar, E. M., Moore, D., Grossman, S. A.
2018; 9 (1): 766–73
- **Advances in the Management of Primary Mediastinal Large B-Cell Lymphoma** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
Advani, R. H.
2018; 16 (1): 33–34
- **New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Spinner, M. A., Advani, R. H., Connors, J. M., Azzi, J., Diefenbach, C.
2018; 38: 626–36
- **New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?** *American Society of Clinical Oncology Education Book*
Spinner, M. A., Advani, R. H., Connors, J. M., Azzi, J., Diefenbach, C.
2018; 38: 626-636
- **Magnetic Resonance Imaging of Tumor Associated Macrophages: Clinical Translation.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Aghighi, M., Theruvath, A. J., Pareek, A., Pisani, L., Alford, R., Muehe, A. M., Sethi, T. K., Holdsworth, S. J., Hazard, F. K., Gratzinger, D., Luna-Fineman, S., Advani, R. H., Spunt, et al
2018
- **Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis** *CANCER*
Henderson, T. O., Parsons, S. K., Wroblewski, K. E., Chen, L., Hong, F., Smith, S. M., McNeer, J. L., Advani, R. H., Gascoyne, R. D., Constine, L. S., Horning, S., Bartlett, N. L., Shah, et al
2018; 124 (1): 136–44
- **Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma** *BLOOD*
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Fenton, K., Huebner, D., Pinelli, et al
2017; 130 (25): 2709–17
- **KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Kunder, C. A., Roncador, G., Advani, R. H., Gualco, G., Bacchi, C. E., Sabile, J. M., Lossos, I. S., Nie, K., Tibshirani, R., Green, M. R., Alizadeh, A. A., Natkunam, Y.

2017; 148 (6): 465–76

- **Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Kharfan-Dabaja, M. A., Kumar, A., Ayala, E., Hamadani, M., Reimer, P., Gisselbrecht, C., d'Amore, F., Jantunen, E., Ishida, T., Bazarbachi, A., Foss, F., Advani, R., Fenske, et al
2017; 23 (11): 1826–38
- **Clinical Impact of the 2016 Update to the WHO Lymphoma Classification (vol 18, 45, 2017)** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Lynch, R. C., Gratzinger, D., Advani, R. H.
2017; 18 (10): 60
- **Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)** *ANNALS OF ONCOLOGY*
Dabaja, B. S., Zelenetz, A. D., Ng, A. K., Tsang, R. W., Qi, S., Allen, P. K., Hodgson, D., Ricardi, U., Hoppe, R. T., Advani, R., Mauch, P. M., Constine, L. S., Specht, et al
2017; 28 (9): 2185–90
- **Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium** *HAEMATOLOGICA*
Stevens, W. C., Mendeville, M., Redd, R., Clear, A. J., Bladergroen, R., Calaminici, M., Rosenwald, A., Hoster, E., Hiddemann, W., Gaulard, P., Xerri, L., Salles, G., Klapper, et al
2017; 102 (8): 1413–23
- **PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA**
Witzig, T., Sokol, L., Jacobsen, E., Advani, R., Mondejar, R., Piris, M., Burrows, F., Melvin, C., Mishra, V., Scholz, C., Gualberto, A.
FERRATA STORTI FOUNDATION.2017: 222
- **The landscape of new drugs in lymphoma** *NATURE REVIEWS CLINICAL ONCOLOGY*
Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., Advani, R., Forero, A., Morschhauser, F., Kersten, M. J., Tobinai, K., Zinzani, P. L., Zucca, et al
2017; 14 (6): 335-346
- **Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.** *British journal of haematology*
Tao, L., Clarke, C. A., Rosenberg, A. S., Advani, R. H., Jonas, B. A., Flowers, C. R., Keegan, T. H.
2017
- **Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.**
Jin, M. C., Kurtz, D., Esfahani, M., Scherer, F., Craig, A. M., Soo, J., Khodadoust, M., Saganty, R., Chabon, J. J., Schroers-Martin, J., Stehr, H., Advani, R. H., Rossi, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.**
Soo, J., Kurtz, D., Scherer, F., Craig, A. M., Jin, M. C., Westin, J. R., Rossi, D., Gaidano, G., Advani, R. H., Diehn, M., Alizadeh, A. A.
AMER SOC CLINICAL ONCOLOGY.2017
- **Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network*
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., Benitez, C. M., Bernat, K., Bierman, P. J., Blum, K. A., Chen, R., Dabaja, B., Forero, et al
2017; 15 (5): 608-638
- **Hodgkin Lymphoma Version 1.2017** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., Benitez, C. M., Bernat, K., Bierman, P. J., Blum, K. A., Chen, R., Dabaja, B., Forero, et al
2017; 15 (5): 608-638
- **International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).** *Annals of oncology*
Younes, A., HILDEN, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreundschuh, M., Morschhauser, F., Schoder, H., Zelenetz, et al
2017

- **A Prospective Cohort Study of Patients With Peripheral T-Cell Lymphoma in the United States** *CANCER*
Carson, K. R., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, M. A., Shustov, A. R., Advani, et al
2017; 123 (7): 1174-1183
- **Improving care with portfolio of physician-led cancer quality measures at an academic center**
Porter, J., Smith, A., Winget, M., Rosenthal, E., Seshadri, S., Vetteth, Y., Kiamanesh, E. F., Badwe, A., Advani, R. H., Buyyounouski, M. K., Coutre, S., Dorigo, O., Ganjoo, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Caimi, P., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, et al
2017; 15 (3): 293-311
- **NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.** *Journal of the National Comprehensive Cancer Network*
Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Caimi, P., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, et al
2017; 15 (3): 293-311
- **Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., Hochberg, E., Yalamanchili, S., Kahn, R., Lu, D., Agarwal, P., Dere, R. C., Hsieh, et al
2017; 23 (5): 1167-1176
- **Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia.** *Blood*
Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Demos, M., Kofides, A., Patterson, C. J., Meid, K., Gustine, J., Dubeau, T., Palomba, M. L., Advani, et al
2017
- **T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.** *Journal of the National Cancer Institute*
Casulo, C., O'Connor, O., Shustov, A., Fanale, M., Friedberg, J. W., Leonard, J. P., Kahl, B. S., Little, R. F., Pinter-Brown, L., Advani, R., Horwitz, S.
2017; 109 (2)
- **Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.** *Clinical lymphoma, myeloma & leukemia*
Hsi, E. D., Horwitz, S. M., Carson, K. R., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, M., Collie, A. M., Gruver, et al
2017
- **Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.** *The Lancet. Haematology*
Furman, R. R., Eradat, H. A., DiRienzo, C. G., Hofmeister, C. C., Hayman, S. R., Leonard, J. P., Coleman, M., Advani, R., Chanan-Khan, A., Switzky, J., Liao, Q. M., Shah, D., Jewell, et al
2017; 4 (1): e24-e34
- **Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.** *Current treatment options in oncology*
Lynch, R. C., Gratzinger, D., Advani, R. H.
2017; 18 (7): 45
- **Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center** *Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center*
Porter, J. B.
2017; 13 (8): e673-e682
- **How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach.** *Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging*
Muehe, A. M., Theruvath, A. J., Lai, L., Aghighi, M., Quon, A., Holdsworth, S. J., Wang, J., Luna-Fineman, S., Marina, N., Advani, R., Rosenberg, J., Daldrup-Link, H. E.
2017

- **Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation** *CASE REPORTS IN ONCOLOGY*
Lynch, R. C., Advani, R. H.
2017; 10 (3): 813–18
- **Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry** *LEUKEMIA & LYMPHOMA*
Bartlett, N. L., Smith, M. R., Siddiqi, T., Advani, R. H., O'Connor, O. A., Sharman, J. P., Feldman, T., Savage, K. J., Shustov, A. R., Diefenbach, C. S., Oki, Y., Palanca-Wessels, M. C., Uttarwar, et al
2017; 58 (7): 1607-1616
- **The landscape of new drugs in lymphoma.** *Nature reviews. Clinical oncology*
Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., Advani, R., Forero, A., Morschhauser, F., Kersten, M. J., Tobinai, K., Zinzani, P. L., Zucca, et al
2016
- **A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.** *Cancer*
Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, M. A., Shustov, A. R., Advani, R. H., Feldman, et al
2016
- **Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia**
Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Chen, J., Demos, M., Patterson, C. J., Dubeau, T., Meid, K., Gustine, J., Castillo, J. J., Advani, et al
AMER SOC HEMATOLOGY.2016
- **Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)**
Diefenbach, C. S., Hong, F., David, K. A., Cohen, J., Robertson, M., Advani, R., Palmisiano, N. D., Ambinder, R. F., Kahl, B. S., Ansell, S.
AMER SOC HEMATOLOGY.2016
- **Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma**
Herrera, A. F., Bartlett, N. L., Ramchandren, R., Vose, J. M., Moskowitz, A. J., Feldman, T. A., LaCasce, A. S., Ansell, S. M., Moskowitz, C. H., Fenton, K., Kato, K., Fong, A., Advani, et al
AMER SOC HEMATOLOGY.2016
- **Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy**
Bannerji, R., Brown, J. R., Advani, R. H., Arnason, J., O'Brien, S. M., Allan, J. N., Chavez, J. C., Barnes, J. A., Joyce, R., Ansell, S., Topp, M. S., Adriaens, L., Ufkin, et al
AMER SOC HEMATOLOGY.2016
- **Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia**
Treon, S. P., Tsakmaklis, N., Meid, K., Yang, G., Chen, J. G., Liu, X., Chen, J., Demos, M., Patterson, C. J., Dubeau, T., Gustine, J., Castillo, J. J., Advani, et al
AMER SOC HEMATOLOGY.2016
- **Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-delta,gamma Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab**
Casulo, C., Sancho, J., Van Eygen, K., de Vos, S., Mercadal, S., Johnson, R. J., Bouabdallah, K., Holmes, H., Lemmens, J., Gyan, E., Merli, M., Advani, R. H., Steelman, et al
AMER SOC HEMATOLOGY.2016
- **Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1+Arm 2 Results from a Multicenter, Open-Label Phase 2 Study**
Fowler, N., Nastoupil, L., de Vos, S., Knapp, M., Flinn, I. W., Chen, R. W., Advani, R. H., Bhatia, S., Martin, P., Mena, R., Suzuki, S., Beaupre, D. M., Neuenburg, et al
AMER SOC HEMATOLOGY.2016
- **Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma**

- Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M. A., Connors, J. M., Fenton, K., Huebner, D., Pinelli, et al
AMER SOC HEMATOLOGY.2016
- **Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial**
Kanakry, J. A., Hong, F., Martinez-Maza, O., Horning, S. J., Gordon, L. I., Gascoyne, R. D., Gellert, L. L., Lemas, M., Cheson, B., Advani, R. H., Pohlman, B., Kenkre, V. P., Winter, et al
AMER SOC HEMATOLOGY.2016
 - **A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001**
Ribrag, V., Chavez, J. C., Kaplan, J. B., Vitolo, U., Chandler, J. C., Santoro, A., Corradini, P., Cassier, P., Flinn, I. W., Advani, R., Sangha, R., Isufi, I., Kenkre, et al
AMER SOC HEMATOLOGY.2016
 - **Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma**
Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., Chabon, J. J., Esfahani, M., Liu, C., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
AMER SOC HEMATOLOGY.2016
 - **Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations**
Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Glover, C., Advani, R. H., Maeda, L. S., Gupta, N. K., Levy, R., Kunder, et al
AMER SOC HEMATOLOGY.2016
 - **Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma** *58th Annual Meeting and Exposition of the American-Society-of-Hematology*
Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., Lovejoy, A. F., Chabon, J. J., Liu, C. L., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
AMER SOC HEMATOLOGY.2016
 - **ACR Appropriateness Criteria (R) Recurrent Hodgkin Lymphoma** *ONCOLOGY-NEW YORK*
Winkfield, K. M., Advani, R. H., Ballas, L. K., Dabaja, B. S., Dhakal, S., Flowers, C. R., Ha, C. S., Hoppe, B. S., Mansur, D. B., Mendenhall, N. P., Metzger, M. L., Plataras, J. P., Roberts, et al
2016; 30 (12): 1099-1108
 - **ACR Appropriateness Criteria (R) Hodgkin Lymphoma-Favorable Prognosis Stage I and II** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Dhakal, S., Advani, R., Ballas, L. K., Dabaja, B. S., Flowers, C. R., Ha, C. S., Hoppe, B. S., Mendenhall, N. P., Metzger, M. L., Plataras, J. P., Roberts, K. B., Shapiro, R., Smith, et al
2016; 39 (6): 535-544
 - **Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy** *BLOOD*
Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., Hoos, A., Barrington, S. F., Armand, P.
2016; 128 (21): 2489-2496
 - **Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.** *Leukemia & lymphoma*
Bartlett, N. L., Smith, M. R., Siddiqi, T., Advani, R. H., O'Connor, O. A., Sharman, J. P., Feldman, T., Savage, K. J., Shustov, A. R., Diefenbach, C. S., Oki, Y., Palanca-Wessels, M. C., Uttarwar, et al
2016: 1-10
 - **Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA** *SCIENCE TRANSLATIONAL MEDICINE*
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al
2016; 8 (364)
 - **Classical Hodgkin Lymphoma with Reduced β 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.** *Cancer immunology research*
Roemer, M. G., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., Connelly, C. F., Pak, C. J., Carey, C. D., Daadi, S. E., Chapuy, B., De Jong, D., Hoppe, et al
2016; 4 (11): 910-916

- **Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified** *ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE*
Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., Khoury, J. D., Medeiros, L. J., Ohgami, R. S., O'Malley, D. P., Patel, K. P., Rosenbaum, J. N., Wilson, et al
2016; 140 (11): 1225-1227
- **Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma** *ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE*
Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., Khoury, J. D., Medeiros, L. J., Ohgami, R. S., O'Malley, D. P., Patel, K. P., Rosenbaum, J. N., Wilson, et al
2016; 140 (11): 1228-1230
- **Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499.** *Leukemia*
Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Palletta, E. M., Advani, R. H., Forero-Torres, A., Horning, S. J., Kahl, B. S.
2016
- **BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA**
LaCasce, A., Bociek, G., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S., Crosswell, H., Islas-Ohlmyer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, et al
FERRATA STORTI FOUNDATION.2016: 45–46
- **SEQUENTIAL BRENTUXIMAB VEDOTIN AND ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE FOR OLDER PATIENTS WITH UNTREATED HODGKIN LYMPHOMA: FINDINGS FROM A PHASE II WINDOW STUDY**
Evens, A. M., Hamlin, P. A., Nabhan, C., Advani, R., Fanale, M., Petrich, A., Smith, S., Bociek, G., Winter, J., Gordon, L. I.
FERRATA STORTI FOUNDATION.2016: 20
- **OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA TREATED ON US COOPERATIVE GROUP PROTOCOLS: AN ADULT INTERGROUP (E2496) AND CHILDREN'S ONCOLOGY GROUP (COG AHOD0031) COMPARATIVE ANALYSIS**
Henderson, T. O., Parsons, S. K., Wroblewski, K., Chen, L., Hong, F., Smith, S., McNeer, J., Advani, R., Gascoyne, R. D., Constine, L. S., Horning, S., Bartlett, N. L., Shah, et al
FERRATA STORTI FOUNDATION.2016: 34–35
- **A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPIILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)**
Diefenbach, C. M., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., Fenske, T. S., Advani, R., Kahl, B. S., Ansell, S.
FERRATA STORTI FOUNDATION.2016: 44–45
- **Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.** *Blood*
Leblond, V., Kasrititis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., García-Sanz, R., Gertz, M., Kimby, E., Kyriakou, C., Merlini, G., Minnema, M. C., Morel, et al
2016; 128 (10): 1321-1328
- **NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.** *Journal of the National Comprehensive Cancer Network*
Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, et al
2016; 14 (9): 1067-1079
- **Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, et al
2016; 14 (9): 1067-1079
- **2 Gy×22 for palliative treatment of mantle cell lymphoma.** *Leukemia & lymphoma*
White, E. C., Advani, R., Hoppe, R. T.
2016; 57 (9): 2219-2221
- **ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.** *American journal of clinical oncology*
Roberts, K. B., Younes, A., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., Ha, C. S., Hoppe, B. S., Mendenhall, N. P., Metzger, M. L., Plastaras, J. P., Shapiro, et al

2016; 39 (4): 384-395

- **Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.** *Therapeutic advances in hematology*
Castillo, J. J., Palomba, M. L., Advani, R., Treon, S. P.
2016; 7 (4): 179-186
- **Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.** *Blood*
Matthews, J. M., Bhatt, S., Patricelli, M. P., Nomanbhoy, T. K., Jiang, X., Natkunam, Y., Gentles, A. J., Martinez, E., Zhu, D., Chapman, J. R., Cortizas, E., Shyam, R., Chinichian, et al
2016; 128 (2): 239-248
- **Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring** *RADIOLOGY*
Minamimoto, R., Fayad, L., Advani, R., Vose, J., Macapinlac, H., Meza, J., Hankins, J., Mottaghy, F., Juweid, M., Quon, A.
2016; 280 (1): 220-229
- **Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.** *Clinical advances in hematology & oncology : H&O*
Varma, G., Johnson, T. P., Advani, R. H.
2016; 14 (7): 543-554
- **BIOMARKERS IN RELAPSED/REFRACTORY DLBCL AND FL PATIENTS TREATED WITH POLATUZUMAB VEDOTIN: RESULTS FROM THE PHASE II CLINICAL TRIAL (ROMULUS)**
Penuel, E., Mundt, K., Bourgon, R., Sumiyoshi, T., Flinn, I., Press, O., Patel, M., Advani, R., Venstrom, J. M., Chu, Y. W., Hirata, J.
FERRATA STORTI FOUNDATION.2016: 578
- **Noninvasive molecular subtyping and risk stratification of DLBCL.**
Scherer, F., Kurtz, D., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C., Zhou, L., Glover, C., Advani, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era.**
Keegan, T. M., Clarke, C. A., Rosenberg, A., Advani, R. H., Jonas, B., Flowers, C., Tao, L.
AMER SOC CLINICAL ONCOLOGY.2016
- **A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies.**
Sawas, A., Savage, K. J., Perez, R. P., Advani, R. H., Melhem-Bertrandt, A., Lackey, J., Trave, F., Anand, B., Huang, Y., Vincent, M., Reyno, L. M., O'Connor, O. A.
AMER SOC CLINICAL ONCOLOGY.2016
- **The 2016 revision of the World Health Organization classification of lymphoid neoplasms** *BLOOD*
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., Jaffe, E. S.
2016; 127 (20): 2375-2390
- **Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Lynch, R. C., Advani, R. H.
2016: e376-e385
- **Prognostic role of baseline 18F-FDG PET/CT in DLBCL patients**
Baratto, L., Wu, F., Minamimoto, R., Sabile, J., Advani, R., Mitra, E.
SOC NUCLEAR MEDICINE INC.2016
- **The role of interim 18F-FDG PET/CT in DLBCL patients: SUV max, SUV mean and SUV peak as predictive metabolic parameters of prognosis**
Baratto, L., Wu, F., Minamimoto, R., Sabile, J., Advani, R., Mitra, E.
SOC NUCLEAR MEDICINE INC.2016
- **Prognostic value of LUGANO, EORTC, PERCIST and IHP criteria in patients with diffuse large B cell lymphoma based on 18F-FDG PET/CT**
Wu, F., Baratto, L., Minamimoto, R., Advani, R., Sabile, J., Mitra, E.
SOC NUCLEAR MEDICINE INC.2016
- **Speeding up PET/MR for cancer staging of children and young adults.** *European radiology*

- Aghighi, M., Pisani, L. J., Sun, Z., Klenk, C., Madnawat, H., Fineman, S. L., Advani, R., von Eyben, R., Owen, D., Quon, A., Moseley, M., Daldrup-Link, H. E.
2016: -?
- **Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma.** *American journal of clinical oncology*
Horst, K. C., Fero, K. E., Hancock, S. L., Advani, R. H., Ikeda, D. M., Daniel, B., Rosenberg, S. A., Donaldson, S. S., Hoppe, R. T.
2016; 39 (2): 114-119
 - **Postibrutinib outcomes in patients with mantle cell lymphoma** *BLOOD*
Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., Rule, S., Advani, R., Iberri, D., Phillips, T., Spurgeon, S., Kozin, E., Noto, et al
2016; 127 (12): 1559-1563
 - **A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy** *LEUKEMIA & LYMPHOMA*
Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mitra, E. S., Advani, R. H., Hoppe, R. T.
2016; 57 (3): 604-608
 - **A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.** *Leukemia & lymphoma*
Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mitra, E. S., Advani, R. H., Hoppe, R. T.
2016; 57 (3): 604-608
 - **Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia** *BRITISH JOURNAL OF HAEMATOLOGY*
Xu, L., Hunter, Z. R., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., Liu, X., Kanan, S., Castillo, J. J., Tai, Y., Zehnder, J. L., Brown, J. R., Carrasco, et al
2016; 172 (5): 735-744
 - **Diffuse Large B-Cell Lymphoma Version 1.2016.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, T. M., Lee Harris, et al
2016; 14 (2): 196-231
 - **Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, T. M., Harris, et al
2016; 14 (2): 196-231
 - **Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.** *British journal of haematology*
2016
 - **Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.** *American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting*
Lynch, R. C., Advani, R. H.
2016; 35: e376-85
 - **The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability**
Xu, L., Hunter, Z., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., Liu, X., Kanan, S., Castillo, J. J., Tai, Y., Zehnder, J. L., Brown, J. R., Carrasco, et al
AMER SOC HEMATOLOGY.2015
 - **PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome**
Roemer, M. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C., Sun, H. H., Daadi, S. E., Chapuy, B., de Jong, D., Hoppe, R. T., Neuberg, et al
AMER SOC HEMATOLOGY.2015
 - **Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management**
Iberri, D. J., Kwong, B., Stevens, L., Coutre, S. E., Kim, J., Sabile, J., Advani, R. H.
AMER SOC HEMATOLOGY.2015
 - **Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis**

- Henderson, T. O., Parsons, S. K., Wroblewski, K., Chen, L., Hong, F., Smith, S. M., McNeer, J., Advani, R., Cascoynee, R. D., Constine, L., Horning, S. J., Bartlett, N. L., Shah, et al
AMER SOC HEMATOLOGY.2015
- **Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y-90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499**
Smith, M. R., Li, H., Hong, F., Gordon, L. I., Gascoyne, R. D., Palletta, E., Advani, R. H., Forrero-Torres, A., Horning, S. J., Kahl, B. S.
AMER SOC HEMATOLOGY.2015
 - **Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma**
Fowler, N., Boyd, T. E., Sharman, J. P., Smith, S. M., Clow, F., Chu, A. D., Advani, R. H.
AMER SOC HEMATOLOGY.2015
 - **A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results**
Sawas, A., Savage, K. J., Perez, R., Advani, R. H., Butturini, A., Lackey, J., Trave, F., Anand, B., Huang, Y., Reyno, L., O'Connor, O. A.
AMER SOC HEMATOLOGY.2015
 - **Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma**
LaCasce, A. S., Bociek, G., Sawas, A., Caimi, P. F., Agura, E., Matous, J., Ansell, S., Crosswell, H., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, et al
AMER SOC HEMATOLOGY.2015
 - **A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refractory B-Lineage Non-Hodgkin Lymphoma**
Moskowitz, C. H., Fanale, M. A., Shah, B. D., Advani, R. H., Chen, R., Kim, S., Kostic, A., Liu, T., Peng, J., Forero-Torres, A.
AMER SOC HEMATOLOGY.2015
 - **Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study**
Fowler, N., Nastoupil, L., de Vos, S., Knapp, M., Flinn, I. W., Chen, R., Advani, R. H., Bhatia, S., Martin, P., Mena, R., Suzuki, S., Beaupre, D. M., Neuenburg, et al
AMER SOC HEMATOLOGY.2015
 - **Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)**
Diefenbach, C. S., Hong, F., Cohen, J. B., Robertson, M. J., Ambinder, R. F., Fenske, T. S., Advani, R. H., Kahl, B. S., Ansell, S.
AMER SOC HEMATOLOGY.2015
 - **Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study**
Yasenchak, C. A., Halwani, A., Advani, R., Ansell, S., Budde, L., Burke, J. M., Farber, C. M., Holkova, B., Fayad, L. E., Kolibaba, K. S., Knapp, M., Li, M., Manley, et al
AMER SOC HEMATOLOGY.2015
 - **Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]**
Swinnen, L. J., O'Neill, A., Imus, P. H., Gujar, S., Schiff, D., Kleinberg, L., Advani, R., Dunbar, E., Moore, D. F., Grossman, S.
AMER SOC HEMATOLOGY.2015
 - **Frontline Treatment of CD30+Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up**
Horwitz, S. M., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R., Pro, B., Chen, R., Davies, A. J., Illidge, T., Huebner, D., Kennedy, D. A., Fanale, M. A.
AMER SOC HEMATOLOGY.2015
 - **Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia**
Thomas, S. K., Harb, W. A., Beck, J., Nashat, G., Palomba, M., Ansell, S. M., Eradat, H., Libby, E. N., Advani, R. H., Hajdenberg, J., Heffner, L. T., Hoffman, J., Vesole, et al
AMER SOC HEMATOLOGY.2015
 - **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al

AMER SOC HEMATOLOGY.2015

- **ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma.** *American journal of clinical oncology*
Dabaja, B. S., Advani, R., Hodgson, D. C., Dhakal, S., Flowers, C. R., Ha, C. S., Hoppe, B. S., Mendenhall, N. P., Metzger, M. L., Plastaras, J. P., Roberts, K. B., Shapiro, R., Smith, et al
2015; 38 (6): 610-620
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*
Kim, Y. H., Tavallae, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al
2015; 33 (32): 3750-3758
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*
Kim, Y. H., Tavallae, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al
2015; 33 (32): 3750-3758
- **Long-term safety and efficacy of single-agent ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study**
Dreyling, M., Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, et al
KARGER.2015: 18–19
- **Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging.** *Current treatment options in oncology*
Iberri, D. J., Hoppe, R. T., Advani, R. H.
2015; 16 (9): 360-?
- **Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.**
Poggesi, I., Sardu, M., Marostica, E., Sukbuntherng, J., Chang, B. Y., de Jong, J., de Trixhe, X., Vermeulen, A., De Nicolao, G., O'Brien, S., Byrd, J. C., Advani, R. H., James, et al
AMER ASSOC CANCER RESEARCH.2015
- **Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort** *AMERICAN JOURNAL OF HEMATOLOGY*
Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., Gascoyne, R. D., Abramson, J. S., Petrich, A. M., Hernandez-Ilizaliturri, F. J., Al-Mansour, Z., Adeimy, C., Hemminger, et al
2015; 90 (9): 778-783
- **Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies** *BRITISH JOURNAL OF HAEMATOLOGY*
Roberts, A. W., Advani, R. H., Kahl, B. S., Persky, D., Sweetenham, J. W., Carney, D. A., Yang, J., Busman, T. B., Enschede, S. H., Humerickhouse, R. A., Seymour, J. F.
2015; 170 (5): 669-678
- **Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.** *American journal of hematology*
Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., Gascoyne, R. D., Abramson, J. S., Petrich, A. M., Hernandez-Ilizaliturri, F. J., Al-Mansour, Z., Adeimy, C., Hemminger, et al
2015; 90 (9): 778-783
- **A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402** *BRITISH JOURNAL OF HAEMATOLOGY*
Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., Kahl, B. S., Advani, R. H., Horning, S. J.
2015; 170 (5): 679-686
- **Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results** *BLOOD*
Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, et al
2015; 126 (6): 739-745

- **Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma** *NATURE MEDICINE*
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C., Williams, P. M., Shaffer, A. L., Gerecitano, J., de Vos, S., Goy, A., Kenkre, et al
2015; 21 (8): 922-926
- **In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs** *MAYO CLINIC PROCEEDINGS*
Tefferi, A., Rajkumar, S., Gertz, M. A., Kyle, R. A., Kantarjian, H., Allison, J., Bast, R. C., Cortes, J., Fidler, I. J., Freireich, E., Gutterman, J., Hong, W., Hortobagyi, et al
2015; 90 (8): 996–1000
- **Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.** *Leukemia*
Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., STAIGER, A., Chai, A., Sandmann, T., MADLE, H., Dörken, B., Chu, Y., Chen, et al
2015; 29 (7): 1578-1586
- **Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes** *LEUKEMIA*
Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., STAIGER, A., Chai, A., Sandmann, T., MADLE, H., Doerken, B., Chu, Y., Chen, et al
2015; 29 (7): 1578-1586
- **Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.** *Blood*
Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., Takahashi, K., Glover, C., Keane, C., Kihira, S., Visser, B., Callahan, J., Kong, et al
2015; 125 (24): 3679-3687
- **TWO DOSES OF POLATUZUMAB VEDOTIN (POV, ANTI-CD79B ANTI-BODY-DRUG CONJUGATE) PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE LEVEL**
Sharman, J., Flinn, I., Advani, R., Diefenbach, C., Kolibaba, K., Press, O., Sehn, L., Chen, A., Salles, G., Tilly, H., Cheson, B., Assouline, S., Dreyling, et al
FERRATA STORTI FOUNDATION.2015: 272
- **INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT**
Kim, S. J., Park, Y., Chang, M. H., Oh, S. Y., Kwak, J. Y., Yang, D. H., Kim, J. S., Eom, H. S., Won, J. H., Won, Y. W., Do, Y. R., Mun, Y. C., Suh, et al
FERRATA STORTI FOUNDATION.2015: 5
- **IBRUTINIB IN PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA IS HIGHLY ACTIVE, PRODUCES DURABLE RESPONSES, AND IS IMPACTED BY MYD88 AND CXCR4 MUTATION STATUS**
Treon, S., Tripsas, C., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K., Yang, G., Cao, Y., Xu, L., Patterson, C., Rödiger, S., Zehnder, et al
FERRATA STORTI FOUNDATION.2015: 311
- **Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study** *LANCET ONCOLOGY*
Palanca-Wessels, M. C., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., Patel, M. R., Sangha, R., Hagenbeek, A., Advani, R., Tilly, H., Casasnovas, O., Press, et al
2015; 16 (6): 704-715
- **Management of nodular lymphocyte predominant Hodgkin lymphoma** *HEMATOLOGICAL ONCOLOGY*
Advani, R. H., Hoppe, R. T.
2015; 33: 90-95
- **First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy.**
Brownstein, C. M., Adriaens, L., Bannerji, R., Chavez, J. C., Levy, R., Ansell, S., Advani, R. H., Patel, S., Kostic, A., Trail, P., Lowy, I., Kohrt, H.
AMER SOC CLINICAL ONCOLOGY.2015
- **Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.**
Khodadoust, M., Chu, M., Czerwinski, D., McDonald, K., Long, S., Kohrt, H., Hoppe, R. T., Advani, R. H., Lowsky, R., Levy, R.
AMER SOC CLINICAL ONCOLOGY.2015
- **Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).**

- Bartlett, N. L., Farber, C. M., Yasenachak, C. A., Ansell, S., Advani, R. H., Knapp, M. H., Fayad, L., Kolibaba, K. S., Patel-Donnelly, D., Seetharam, M., Yimer, H., Manley, T., Burke, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.**
Advani, R. H., Flinn, I., Sharman, J., Diefenbach, C., Kolibaba, K. S., Press, O. W., Sehn, L., Chen, A. I., Salles, G. A., Tilly, H., Cheson, B. D., Assouline, S. E., Dreyling, et al
AMER SOC CLINICAL ONCOLOGY.2015
 - **CD30+expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project**
Federico, M., Bellei, M., Luminari, S., Horwitz, S. M., Montoto, S., Zucca, E., Pileri, S. A., Ko, Y., Zinzani, P., Connors, J. M., Foss, F. M., Polliack, A., Cabrera, et al
AMER SOC CLINICAL ONCOLOGY.2015
 - **A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412).**
Diefenbach, C., Li, H., Kahl, B. S., Robertson, M. J., Cohen, J., Advani, R. H., Ambinder, R., Fenske, T. S., Ansell, S.
AMER SOC CLINICAL ONCOLOGY.2015
 - **Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)**
Scherer, F., Kurtz, D., Green, M., Newman, A. M., Klass, D. M., Zhou, L., Krishnan, R., Liu, C., Glover, C., Ohgami, R. S., Hicks, R. J., Keane, C., Kong, et al
AMER SOC CLINICAL ONCOLOGY.2015
 - **IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY**
Rule, S., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Papat, R., Avivi, Advani, R., Le Gouill, S., Horowitz, N., Yuan, Z., Kranenburg, B., Zhuang, S. H., et al
ELSEVIER SCIENCE INC.2015: A300–A301
 - **Prospective multicenter comparison of early interim F-18-FLT PET/CT versus F-18-FDG PET/CT**
Minamimoto, R., Fayad, L., Advani, R., Vose, J., Macapinlac, H., Meza, J., Hankins, J., Mottaghy, F., Juweid, M., Quon, A.
SOC NUCLEAR MEDICINE INC.2015
 - **Hodgkin Lymphoma, Version 2.2015** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., Benitez, C. M., Bierman, P. J., Blum, K. A., Chen, R., Dabaja, B., Forero, A., Gordon, et al
2015; 13 (5): 554-586
 - **Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
King, M. T., Donaldson, S. S., Link, M. P., Natkunam, Y., Advani, R. H., Hoppe, R. T.
2015; 92 (1): 67-75
 - **Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era.** *International journal of radiation oncology, biology, physics*
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., Advani, R. H., Hoppe, R. T.
2015; 92 (1): 99-106
 - **Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study**
Rule, S., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Papat, R., Avivi, I., Advani, R., Le Gouill, S., Horowitz, N., Yuan, Z., Kranenburg, B., Zhuang, et al
WILEY-BLACKWELL.2015: 59
 - **A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma** *BRITISH JOURNAL OF HAEMATOLOGY*
Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Belt, R. J., Jacobsen, E. D., Laurent, G., Ben-Yehuda, D., Beylot-Barry, et al
2015; 168 (6): 811-819
 - **Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.** *Journal of the National Comprehensive Cancer Network*

- Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, et al
2015; 13 (3): 326-362
- **Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT)** *JOURNAL OF CLINICAL ONCOLOGY*
Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., Advani, R. H., Go, R. S., Habermann, T. M., Leach, J. W., O'Connor, B., Schuster, S. J., Cella, et al
2015; 33 (7)
 - **Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).** *Journal of clinical oncology*
Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., Advani, R. H., Go, R. S., Habermann, T. M., Leach, J. W., O'Connor, B., Schuster, S. J., Cella, et al
2015; 33 (7): 740-748
 - **Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma** *LEUKEMIA & LYMPHOMA*
Illidge, T., Bouabdallah, R., Chen, R., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., Shustov, A. R., Tilly, H., Trippett, T. M., Gibb, A., Grove, L. E., Advani, R.
2015; 56 (3): 703-710
 - **Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, et al
2015; 13 (3): 326-362
 - **Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression** *BLOOD*
Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., Spitzer, G., Palanca-Wessels, M. C., Kennedy, D. A., Levine, P., Yang, J., Bartlett, N. L.
2015; 125 (9): 1394-1402
 - **Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution.** *Biology of blood and marrow transplantation*
Garfin, P. M., Link, M. P., Donaldson, S. S., Advani, R. H., Luna-Fineman, S., Kharbanda, S., Porteus, M., Weinberg, K. I., Agarwal-Hashmi, R.
2015; 21 (2): 326-334
 - **Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Marostica, E., Sukbuntherng, J., Louny, D., de Jong, J., de Tria, X. W., Vermeulen, A., De Nicolao, G., O'Brien, S., Byrd, J. C., Advani, R., McGreivoy, J., Poggesi, I.
2015; 75 (1): 111-121
 - **Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.** *Blood*
Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, et al
2015; 126 (6): 739-45
 - **Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.** *Leukemia & lymphoma*
Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Stuart, R., Bartlett, N. L., Forero-Torres, A., Kuliczowski, K., Belada, D., Ng, E., Drachman, J. G.
2015; 56 (9): 2569-2578
 - **Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study**
Wang, M., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, et al
AMER SOC HEMATOLOGY.2014
 - **Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome**

Kritharis, A., Kanakry, J. A., Sehn, L. H., Feldman, T., Kroll, A., Gascoyne, R. D., Petrich, A. M., Abramson, J. S., Hernandez-Ilizaliturri, F., Al-Mansour, Z., Adeimy, C., Hemminger, J., Bartlett, et al
AMER SOC HEMATOLOGY.2014

- **Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study**
Bartlett, N. L., Smith, M. R., Advani, R., Feldman, T., Savage, K. J., Palanca-Wessels, M., Siddiqi, T.
AMER SOC HEMATOLOGY.2014
- **Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma**
Moskowitz, C. H., Forero-Torres, A., Shah, B. D., Advani, R., Hamlin, P., Kim, S., Kostic, A., Sandalic, L., Zhao, B., Fanale, M. A.
AMER SOC HEMATOLOGY.2014
- **Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)**
Pinter-Brown, L., Foss, F. M., Carson, K. R., Horwitz, S. M., Rosen, S. T., Pro, B., Federico, M., Gisselbrecht, C., Hsi, E. D., Shustov, A. R., Advani, R., Feldman, T., Lechowicz, et al
AMER SOC HEMATOLOGY.2014
- **Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma**
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandern, R., Fanale, M. A., Connors, J. M., Wang, Y., Huebner, D., Kennedy, et al
AMER SOC HEMATOLOGY.2014
- **Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma**
Morschhauser, F., Flinn, I., Advani, R. H., Diefenbach, C. S., Kolibaba, K., Press, O. W., Sehn, L. H., Chen, A. I., Salles, G., Tilly, H., Cheson, B. D., Assouline, S., Dreyling, et al
AMER SOC HEMATOLOGY.2014
- **Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study**
Yasenchak, C. A., Farber, C. M., Budde, L., Ansell, S. M., Advani, R., Holkova, B., Halwani, A., Knapp, M., Fayad, L., Kolibaba, K. S., Patel-Donnelly, D., Seetharam, M., Manley, et al
AMER SOC HEMATOLOGY.2014
- **Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy**
LaCasce, A., Bociek, R., Matous, J., Sawas, A., Caimi, P., Ansell, S. M., Islas-Ohlmayer, M., Cheung, E., Agura, E., Behler, C., Crosswell, H., Vose, J. M., Josephson, et al
AMER SOC HEMATOLOGY.2014
- **Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma**
Kohrt, H. E., Chu, J., Brody, J., Czerwinski, D. K., Chester, C., Sadaram, M., Advani, R., Kim, Y. H., Hoppe, R. T., Knox, S. J., Wapnir, I., Tibshirani, R. J., Levy, et al
AMER SOC HEMATOLOGY.2014
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression**
Kim, Y. H., Tavallae, M., Rozati, S., Sundram, U., Salva, K., Wood, G. S., Li, S., Krathen, M., Nagpal, S., Reddy, S., Armstrong, R., Hoppe, R. T., Pulitzer, et al
AMER SOC HEMATOLOGY.2014
- **Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy**
Wang, M., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., Avivi, I., Advani, R., Le Gouill, S., Horowitz, N., Yuan, Z., Kranenburg, B., Rizo, et al
AMER SOC HEMATOLOGY.2014
- **ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma** *JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY*
Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., Hoppe, B. S., Mendenhall, N. P., Metzger, M. L., Plastaras, J. P., Roberts, K. B., Shapiro, R., Smith, et al
2014; 11 (11): 1026-1033
- **ACR appropriateness criteria follow-up of Hodgkin lymphoma.** *Journal of the American College of Radiology*
Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., Hoppe, B. S., Mendenhall, N. P., Metzger, M. L., Plastaras, J. P., Roberts, K. B., Shapiro, R., Smith, et al

2014; 11 (11): 1026-1033 e3

- **Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study** *JOURNAL OF CLINICAL ONCOLOGY*
Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., Chen, R. W., Davies, A., Illidge, T., Huebner, D., Kennedy, D. A., Shustov, A. R.
2014; 32 (28): 3137-?
- **Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies**
Marostica, E., Sukbuntherng, J., Loury, D., Jong, J. D., de Trixhie, X., Vermeulen, A., de Nicolao, G., O'Brien, S., Byrd, J. C., Advani, R., McGreivy, J., Poggesi, I.
AMER ASSOC CANCER RESEARCH.2014
- **Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.** *Journal of clinical oncology*
Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., Chen, R. W., Davies, A., Illidge, T., Huebner, D., Kennedy, D. A., Shustov, A. R.
2014; 32 (28): 3137-3143
- **Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma**
Stilgenbauer, S., Rule, S., Wang, M. L., Martin, P., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J., Williams, M., Barrientos, J. C., Chmielowska, E., Radford, et al
KARGER.2014: 34-35
- **Non-Hodgkin's Lymphomas, Version 4.2014.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, M. J., Harris, et al
2014; 12 (9): 1282-1303
- **Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Management in the Modern Era**
King, M., Donaldson, S., Link, M., Advani, R., Hoppe, R.
ELSEVIER SCIENCE INC.2014: S67-S68
- **BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP**
Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., Chen, R. W., Davies, A., Illidge, T., Huebner, D., Kennedy, D. A., Shustov, A. R.
OXFORD UNIV PRESS.2014
- **Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era**
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., Hoppe, R. T.
ELSEVIER SCIENCE INC.2014: S677-S678
- **Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus** *BLOOD*
Dimopoulos, M. A., Kastiris, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., Leleu, X., Garcia-Sanz, R., Munshi, N., Anderson, K. C., Terpos, E., Ghobrial, I. M., Morel, et al
2014; 124 (9): 1404-1411
- **Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.** *Therapeutic advances in hematology*
Aalipour, A., Advani, R. H.
2014; 5 (4): 121-133
- **ACR appropriateness Criteria® pediatric Hodgkin lymphoma.** *Pediatric blood & cancer*
Terezakis, S. A., Metzger, M. L., Hodgson, D. C., Schwartz, C. L., Advani, R., Flowers, C. R., Hoppe, B. S., Ng, A., Roberts, K. B., Shapiro, R., Wilder, R. B., Yunes, M. J., Constine, et al
2014; 61 (7): 1305-1312
- **A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors** *JOURNAL OF HEMATOLOGY & ONCOLOGY*
de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., Furman, R. R., Winter, J. N., Kaplan, H., Timmerman, J., Whiting, N. C., Drachman, J. G., Advani, et al
2014; 7

- **Non-Hodgkin's lymphomas, version 2.2014.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, et al
2014; 12 (6): 916-946
- **Non-Hodgkin's Lymphomas, Version 2.2014.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, et al
2014; 12 (6): 916-946
- **PRELIMINARY RESULTS OF A PHASE II RANDOMIZED STUDY (ROMULUS) OF POLATUZUMAB VEDOTIN OR PINATUZUMAB VEDOTIN PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)**
Morschhauser, F., Flinn, I., Advani, R., Sehn, L., Kolibaba, K., Press, O., Salles, G., Diefenbach, C., Tilly, H., Assouline, S., Chen, A., Dreyling, M., Hagenbeek, et al
FERRATA STORTI FOUNDATION.2014: 525
- **PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME**
Rule, S., Wang, M. L., Martin, P., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J., Williams, M., Barrientos, J. C., Chmielowska, E., Radford, J. A., Stilgenbauer, et al
FERRATA STORTI FOUNDATION.2014: 150
- **Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PIV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).**
Morschhauser, F., Flinn, I., Advani, R. H., Sehn, L., Kolibaba, K. S., Press, O. W., Salles, G. A., Diefenbach, C., Tilly, H., Assouline, S. E., Chen, A., Dreyling, M. H., Hagenbeek, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.**
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., Hoppe, R. T.
AMER SOC CLINICAL ONCOLOGY.2014
- **Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).**
Forero-Torres, A., Moskowitz, C., Advani, R. H., Shah, B. D., Kostic, A., Albertson, T. M., Sandalic, L., Zhao, B., Fanale, M. A.
AMER SOC CLINICAL ONCOLOGY.2014
- **Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.**
Kurtz, D., Green, M. R., Bratman, S., Liu, C., Glover, C., Keane, C., Kong, K., Faham, M., Miklos, D., Advani, R. H., Levy, R., Hertzberg, M. S., Gandhi, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin BLOOD**
Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O'Connor, O. A., Siddiqi, T., Kennedy, D. A., Oki, Y.
2014; 123 (20): 3095-3100
- **A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era BRITISH JOURNAL OF HAEMATOLOGY**
Hosein, P. J., Maragulia, J. C., Salzberg, M. P., Press, O. W., Habermann, T. M., Vose, J. M., Bast, M., Advani, R. H., Tibshirani, R., Evens, A. M., Islam, N., Leonard, J. P., Martin, et al
2014; 165 (3): 358-363
- **Multicenter study for comparison of FLT and FDG PET/CT for early interim therapy monitoring of diffuse large B-cell lymphoma**
Minamimoto, R., Vose, J., Advani, R., Fayad, L., Macapinlac, H., Meza, J., Hankins, J., Mottaghy, F., Juweid, M., Quon, A.
SOC NUCLEAR MEDICINE INC.2014
- **Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).** *Leukemia & lymphoma*
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., Habermann, T. M., Kahl, B. S., Advani, R. H.
2014; 55 (4): 768-772
- **Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma.** *Annals of oncology : official journal of the European Society for Medical Oncology*

- Horst, K. C., Hancock, S. L., Ognibene, G., Chen, C., Advani, R. H., Rosenberg, S. A., Donaldson, S. S., Hoppe, R. T.
2014; 25 (4): 848–51
- **Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma.** *Annals of oncology*
Horst, K. C., Hancock, S. L., OGNIBENE, G., Chen, C., Advani, R. H., Rosenberg, S. A., Donaldson, S. S., Hoppe, R. T.
2014; 25 (4): 848-851
 - **Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies** *JOURNAL OF HEMATOLOGY & ONCOLOGY*
Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., Advani, R., Matous, J. V., Ramchandren, R., Rosenblatt, J. D., Huebner, D., Levine, P., Grove, et al
2014; 7
 - **Bulky Mediastinal Classical Hodgkin Lymphoma in Young Women** *ONCOLOGY-NEW YORK*
Percival, M. M., Hoppe, R. T., Advani, R. H.
2014; 28 (3): 253+
 - **A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations**
Ohgami, R. S., Chen, J. S., Advani, R., Natkunam, Y., Warnke, R. A.
NATURE PUBLISHING GROUP.2014: 366A–367A
 - **A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma in the First Salvage Setting: Interim Results**
LaCasce, A., Sawas, A., Bociek, R., Ansell, S., Vose, J., O'Meara, M., Advani, R.
ELSEVIER SCIENCE INC.2014: S161
 - **Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope?** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Diefenbach, C., Advani, R.
2014; 28 (1): 105-?
 - **A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations**
Ohgami, R. S., Chen, J. S., Advani, R., Natkunam, Y., Warnke, R. A.
NATURE PUBLISHING GROUP.2014: 366A–367A
 - **A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.** *Journal of hematology & oncology*
de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., Furman, R. R., Winter, J. N., Kaplan, H., Timmerman, J., Whiting, N. C., Drachman, J. G., Advani, et al
2014; 7: 44-?
 - **Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.** *Journal of hematology & oncology*
Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., Advani, R., Matous, J. V., Ramchandren, R., Rosenblatt, J. D., Huebner, D., Levine, P., Grove, et al
2014; 7: 24-?
 - **Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.** *Journal of clinical oncology*
Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., Robinson, B. K., Otis, S., Nadav Dagan, L., Abdallah, R., Kroll-Desrosiers, A., Yarber, J. L., Sandoval, et al
2013; 31 (32): 4132-4139
 - **Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.** *Journal of clinical oncology*
Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., Robinson, B. K., Otis, S., Nadav Dagan, L., Abdallah, R., Kroll-Desrosiers, A., Yarber, J. L., Sandoval, et al
2013; 31 (32): 4132-4139
 - **Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.** *British journal of haematology*
Aalipour, A., Advani, R. H.
2013; 163 (4): 436-443
 - **Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines** *LANCET ONCOLOGY*
Tan, D., Tan, S. Y., Lim, S. T., Kim, S. J., Kim, W., Advani, R., Kwong, Y.
2013; 14 (12): E548-E561

- **Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013)** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D., Weng, W., Negrin, R. S., Carlton, V., Faham, M., Levy, R., Barrett, J.
2013; 19 (10): 1530
- **ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma** *ONCOLOGY-NEW YORK*
Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., Metzger, M. L., Plataras, J. P., Roberts, K. B., Shapiro, R., Terezakis, S. A., Winkfield, K. M., Younes, et al
2013; 27 (8): 786-794
- **ACR Appropriateness Criteria: Localized nodal indolent lymphoma.** *Oncology (Williston Park, N.Y.)*
Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., Metzger, M. L., Plataras, J. P., Roberts, K. B., Shapiro, R., Terezakis, S. A., Winkfield, K. M., Younes, et al
2013; 27 (8): 786-794
- **A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study** *LEUKEMIA & LYMPHOMA*
Foss, F. M., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M. R., Komrokji, R., Pendergrass, K., Bolejack, V.
2013; 54 (7): 1373-1379
- **Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Han, T. H., Chen, R., Advani, R., Berryman, R. B., Smith, S. E., Forero-Torres, A., Rosenblatt, J. D., Smith, M. R., Zain, J., Hunder, N. N., Engert, A.
2013; 72 (1): 241-249
- **UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA**
Rule, S., Wang, M., Martin, P., Auer, R., Kahl, B., Jurczak, W., Advani, R., Romaguera, J., Williams, M., Barrientos, J., Chmielowska, E., Radford, J., Stilgenbauer, et al
FERRATA STORTI FOUNDATION.2013: 489
- **THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB (PCI-32765), HAS PREFERENTIAL ACTIVITY IN THE ACTIVATED B CELL-LIKE (ABC) SUBTYPE OF RELAPSED/REFRACTORY (R/R) DLBCL: INTERIM PHASE 2 RESULTS**
deVos, S., Wilson, W., Gerecitano, J., Goy, A., Kenkre, V., Barr, P., Blum, K., Shustov, A., Advani, R., Fowler, N., Vose, J., Lih, C., Williams, et al
FERRATA STORTI FOUNDATION.2013: 490
- **Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Glenn, M. J., Gockerman, J. P., Gordon, et al
2013; 11 (3): 257-273
- **Non-Hodgkin's lymphomas, version 1.2013.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Glenn, M. J., Gockerman, J. P., Gordon, et al
2013; 11 (3): 257-272
- **Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Scott, D. W., Chan, F. C., Hong, F., Rogic, S., Tan, K. L., Meissner, B., Ben-Neriah, S., Boyle, M., Kridel, R., Telenius, A., Woolcock, B. W., Farinha, P., Fisher, et al
2013; 31 (6): 692-700
- **Cancer Vaccines and T Cell Therapy** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., Weng, W., Negrin, R. S., Carlton, V., Faham, M., Levy, R., Barrett, J.
2013; 19 (1): S97-S101
- **Non-Hodgkin's Lymphomas, version 3.2012.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L., Glenn, M. J., Gockerman, J. P., Gordon, et al
2012; 10 (12): 1487-1498

- **Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L., Glenn, M. J., Gockerman, J. P., Gordon, et al
2012; 10 (12): 1487-1498
- **A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results**
Jacobsen, E. D., Advani, R. H., Oki, Y., Sharman, J., Horwitz, S. M., Forero-Torres, A., O'Connor, O. A., Shustov, A. R., Siddiqi, T., Grove, L. E., Bartlett, N. L.
AMER SOC HEMATOLOGY.2012
- **The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma**
Fowler, N. H., Advani, R. H., Sharman, J., Smith, S. M., McGreivy, J., Kunkel, L., Vina Troung, Zhou, C., Boyd, T. E.
AMER SOC HEMATOLOGY.2012
- **A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).**
Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., Advani, R. H., Kahl, B. S., Horning, S. J.
AMER SOC HEMATOLOGY.2012
- **Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity**
Salzberg, M. P., Maragulia, J. C., Press, O. W., Habermann, T. M., Vose, J. M., Bast, M., Advani, R. H., Evens, A. M., Islam, N., Leonard, J. P., Martin, P., Hosein, P. J., Zelenetz, et al
AMER SOC HEMATOLOGY.2012
- **Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma**
Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J. V., Ramchandren, R., Fanale, M. A., Connors, J. M., Yang, Y., Kennedy, D. A., Shustov, et al
AMER SOC HEMATOLOGY.2012
- **Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up**
Wang, M., Rule, S. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., McGreivy, J., Clow, F., Stevens-Brogan, M., Kunkel, et al
AMER SOC HEMATOLOGY.2012
- **Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up**
Wang, M., Rule, S. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., McGreivy, J., Clow, F., Stevens-Brogan, M., Kunkel, et al
AMER SOC HEMATOLOGY.2012
- **A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Advani, R., Lebmic, D., Brunvand, M., Chen, A. I., Goy, A., Chang, J. E., Maeda, L. S., Ho, W., Kahn, R., Lu, D., Su, M., Chu, Y., Cheson, et al
AMER SOC HEMATOLOGY.2012
- **Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Krathen, M., Sundram, U., Bashey, S., Sutherland, K., Salva, K., Wood, G. S., Advani, R. H., Hoppe, R. T., Reddy, S., Armstrong, R., Nagpal, S., Pulitzer, M., Horwitz, et al
AMER SOC HEMATOLOGY.2012
- **A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Palanca-Wessels, M. C., Flinn, I. W., Sehn, L. H., Patel, M., Sangha, R., Czuczman, M. S., Salles, G. A., Morschhauser, F., Advani, R., Press, O. W., Ho, W., Kahn, R., Lu, et al
AMER SOC HEMATOLOGY.2012
- **Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Yang, D. T., Paietta, E., Advani, R. H., Horning, S. J.

AMER SOC HEMATOLOGY.2012

- **Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Fanale, M. A., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., Chen, R. W., Davies, A., Midge, T., Kennedy, D. A., Horwitz, S. M.
AMER SOC HEMATOLOGY.2012
- **Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Advani, R. H., Li, H., Hoppe, R. T., Bartlett, N. L., Bennett, J. M., Neuberg, D. S., Cassileth, P. A., Kahl, B. S., Horning, S. J.
AMER SOC HEMATOLOGY.2012
- **in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Czerwinski, D. K., Brody, J., Kohrt, H. E., Hoppe, R. T., Advani, R. H., Levy, R.
AMER SOC HEMATOLOGY.2012
- **Evaluation of Radiation Therapy for NK-T-cell Lymphoma of the Head and Neck**
Chan, C., Zeidan, Y. H., Advani, R., Le, Q., Hoppe, R. T.
ELSEVIER SCIENCE INC.2012: S618-S619
- **SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN IN NEWLY DIAGNOSED PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA**
Fanale, M., Advani, R., Bartlett, N. L., Davies, A., Illidge, T., Kennedy, D. A., Shustov, A. R.
OXFORD UNIV PRESS.2012: 348
- **Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation** *BLOOD*
Gopal, A. K., Ramchandren, R., O'Connor, O. A., Berryman, R. B., Advani, R. H., Chen, R., Smith, S. E., Cooper, M., Rothe, A., Matous, J. V., Grove, L. E., Zain, J.
2012; 120 (3): 560-568
- **Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.**
Advani, R., Oki, Y., Shustov, A. R., Grove, L. E., Bartlett, N.
AMER SOC CLINICAL ONCOLOGY.2012
- **Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Maeda, L. S., Geiger, J. L., Savage, K. J., Rose, J., Pinter-Brown, L. C., Lunning, M. A., Abramson, J. S., Bartlett, N., Vose, J., Drape, J., Muffly, L. S., McMillan, A., Evens, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines** *PLOS ONE*
Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. A., Sheth, S., Kurian, A. W., Ford, et al
2012; 7 (5)
- **Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., Bierman, P. J., Blum, K. A., Chen, R., Dabaja, B., Duron, Y., Forero, A., Gordon, et al
2012; 10 (5): 589-597
- **Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels** *75th Annual Meeting of the Society-for-Investigative-Dermatology*
Bashey, S., Krathen, M., Sutherland, K., Sundram, U., Lingala, B., Horwitz, S., Hoppe, R., Pulitzer, M., Advani, R., Kim, Y.
NATURE PUBLISHING GROUP.2012: S95-S95
- **Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma**
Advani, R., Pro, B., Kennedy, D., Fanale, M.
MOSBY-ELSEVIER.2012: AB4

- **Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease** *RADIATION ONCOLOGY*
Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Hoppe, R. T., Quon, A., Graves, E. E., Loo, B. W., Tran, P. T.
2012; 7
- **In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study** *BLOOD*
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., Tibshirani, R. J., Advani, R. H., Lingala, et al
2012; 119 (2): 355-363
- **A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies** *CLINICAL CANCER RESEARCH*
Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., Han, T. H., Sievers, E. L., Bartlett, N. L.
2012; 18 (1): 248-255
- **Optimal Therapy of Advanced Hodgkin Lymphoma** *HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM*
Advani, R.
2011: 310-316
- **Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Evens, A. M., Advani, R., Lossos, I. S., Press, O. W., Vose, J. M., Hernandez-Ilizaliturri, F. J., Robinson, B. K., Otis, S., Dagan, L. N., Abdallah, R., Kroll, A., Sandoval, J., Yarber, et al
AMER SOC HEMATOLOGY.2011: 45-46
- **Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience**
Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., McMillan, A., Bartlett, N. L.
AMER SOC HEMATOLOGY.2011: 1154
- **Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update**
Advani, R. H., Shustov, A. R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M. A., Connors, J. M., Yang, Y., Kennedy, D. A., Pro, et al
AMER SOC HEMATOLOGY.2011: 204
- **Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Advani, R. H., Hong, F., Li, H., Kahl, B. S., Pfreundschuh, M., Ziepert, M.
AMER SOC HEMATOLOGY.2011: 681-81
- **A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Furman, R. R., Eradat, H., DiRienzo, C. G., Hayman, S. R., Hofmeister, C. C., Avignon, N. A., Leonard, J. P., Coleman, M., Advani, R., Switzky, J. C., Liao, Q., Shah, D. N., Lisby, et al
AMER SOC HEMATOLOGY.2011: 1581-81
- **Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., Faham, M., Advani, R., Kohrt, H. E., Alizadeh, A. A., Negrin, R. S., Weng, W., Sheehan, et al
AMER SOC HEMATOLOGY.2011: 1323-23
- **Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Treon, S. P., Tripsas, C. K., Ioakimidis, L., Warren, D., Patterson, C., Heffner, L., Eradat, H., Gregory, S. A., Thomas, S., Advani, R., Baz, R., Badros, A. Z., Matous, et al
AMER SOC HEMATOLOGY.2011: 1273-74
- **The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Wang, L., Martin, P., Blum, K. A., Kahl, B. S., Maeda, L. S., Advani, R., Williams, M. E., Rule, S., Rodriguez, S., Pang, C., Hedrick, E., Goy, A.
AMER SOC HEMATOLOGY.2011: 203-4

- **Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Illidge, T., Bouabdallah, R., Chen, R. W., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., Rosenblatt, J. D., Shustov, A. R., Tilly, H., Trippett, T., Grove, L. E., Advani, R. H.
AMER SOC HEMATOLOGY.2011: 1335–36
- **Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Advani, R., Hong, F., Gordon, L. I., Gascoyne, R. D., Wagner, H., Hoppe, R. T., Fisher, R. I., Bartlett, N. L., Kahl, B. S., Stiff, P., Cheson, B. D., Belch, A. R., Friedberg, et al
AMER SOC HEMATOLOGY.2011: 696–97
- **Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Rubenstein, J. L., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., Krouwer, H., Kadoch, C., Munster, P., Cha, S., Shuman, M. A., Damon, L. E.
AMER SOC HEMATOLOGY.2011: 438–39
- **Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (SALCL)** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Forero-Torres, A., Berryman, R. B., Advani, R. H., Bartlett, N. L., Chen, R. W., Fanale, M. A., Gopal, A. K., O'Connor, O. A., Olshefski, R., Smith, S. E., Grove, L. E., Matous, J.
AMER SOC HEMATOLOGY.2011: 1585–86
- **Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies** *INVESTIGATIONAL NEW DRUGS*
Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., Losa, R., Sierra, M. I., Sikic, B. I.
2011; 29 (5): 971-977
- **Hodgkin lymphoma.** *Journal of the National Comprehensive Cancer Network*
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., Blum, K. A., Dabaja, B., Duron, Y., Forero, A., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Hochberg, et al
2011; 9 (9): 1020-1058
- **NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., Blum, K. A., Dabaja, B., Duron, Y., Forero, A., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Hochberg, et al
2011; 9 (9): 1020-1058
- **Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment** *BLOOD*
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., Goldstein, M. J., Zhao, S., Natkunam, Y., Advani, R. H., Gascoyne, R. D., Briones, J., Tibshirani, et al
2011; 118 (5): 1350-1358
- **Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus** *OBSTETRICS AND GYNECOLOGY*
Thuong-Thuong Nguyen, T. T., Gubens, M., Arber, D. A., Advani, R., Juretzka, M., Aziz, N.
2011; 118 (2): 486-489
- **IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS** *11th International Conference on Malignant Lymphoma*
Brody, J., Advani, R., Czerwinski, D., Negrin, R., Levy, R.
OXFORD UNIV PRESS.2011: 102–102
- **EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496**
Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N., Connors, J. M., Wagner, H., Gospodarowicz, M., Cheson, B. D., Advani, R., Kahl, B. S., Hoppe, R. T., Horning, et al
OXFORD UNIV PRESS.2011: 117–18
- **DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL)**
Shustov, A., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, et al

OXFORD UNIV PRESS.2011: 125

- **A PHASE 2B TRIAL COMPARING DACETUZUMAB plus R-ICE VS PLACEBO plus R-ICE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA**
Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Bartlett, N. L., Stuart, R., Forero-Torres, A., Kuliczowski, K., Drachman, J. G.
OXFORD UNIV PRESS.2011: 132
- **THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND WELL TOLERATED IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES: FINAL RESULTS FROM A PHASE I STUDY**
Advani, R. H., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B. W., Kolibaba, K. S., Furman, R. R., Buggy, J. J., Loury, D. J., Hedrick, E., Izumi, R., Hamdy, A. M., Fowler, et al
OXFORD UNIV PRESS.2011: 135
- **ABBREVIATED 8 WK CHEMOTHERAPY (CT) plus INVOLVED NODE RADIOTHERAPY (INRT) FOR NON-BULKY STAGE I-II HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE STANFORD G5 STUDY**
Advani, R. H., Horning, S. J., Jonathan, E., Daadi, S., Allen, J., Rosenberg, S. A., Hoppe, R. T.
OXFORD UNIV PRESS.2011: 179
- **OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS** *11th International Conference on Malignant Lymphoma*
YARBER, J. L., Otis, S. A., Robinson, B. K., Gordon, L. I., Winter, J. N., Advani, R. H., Evens, A. M.
OXFORD UNIV PRESS.2011: 191-191
- **PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499** *11th International Conference on Malignant Lymphoma*
Smith, M. R., Li, H., Gordon, L., Gascoyne, R., Paietta, E., Forero-Torres, A., Kahl, B., Advani, R., Hong, F., Horning, S.
OXFORD UNIV PRESS.2011: 86-87
- **Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized US Intergroup Trial E2496**
Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N., Connors, J. M., Wagner, H., Gospodarowicz, M. K., Cheson, B. D., Advani, R., Kahl, B. S., Hoppe, R. T., Horning, et al
AMER SOC CLINICAL ONCOLOGY.2011
- **Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results.**
Brody, J., Advani, R., Weng, W., Czerwinski, D., Alizadeh, A. A., Kohrt, H. E., Negrin, R., Levy, R.
AMER SOC CLINICAL ONCOLOGY.2011
- **Non-Hodgkin's Lymphomas** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Glenn, M. J., Gockerman, J. P., Gordon, L. I., Harris, et al
2011; 9 (5): 484-560
- **ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II** *JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY*
Das, P., Ng, A., Constine, L. S., Advani, R., Flowers, C., Friedberg, J., Hodgson, D. C., Schwartz, C. L., Wilder, R. B., Wilson, L. D., Yunes, M. J.
2011; 8 (5): 302-308
- **Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-centre case series**
Gopal, A. K., Ramchandren, R., Berryman, R. B., Advani, R. H., Chen, R., Smith, S., Cooper, M., Engert, A., Matous, J., Zain, J., Grove, L. E., Hunder, N. N., O'Connor, et al
NATURE PUBLISHING GROUP.2011: S36
- **CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma** *SCIENCE TRANSLATIONAL MEDICINE*
Burlington, B., Yue, P., Shi, X., Advani, R., Lau, J. T., Tan, J., Stinson, S., Stinson, J., Januario, T., de Vos, S., Ansell, S., Forero-Torres, A., Fedorowicz, et al
2011; 3 (74)
- **Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Olsen, E. A., Rook, A. H., Zic, J., Kim, Y., Porcu, P., Querfeld, C., Wood, G., Demierre, M., Pittelkow, M., Wilson, L. D., Pinter-Brown, L., Advani, R., Parker, et al

2011; 64 (2): 352-404

- **Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., Zhao, S., Natkunam, Y., Advani, R., Gascoyne, R. D., Briones, J., Tibshirani, R. J., Myklebust, et al
AMER SOC HEMATOLOGY.2010: 836-37
- **The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study**
Fowler, N., Sharman, J., Smith, S. M., Boyd, T., Grant, B., Kolibaba, K. S., Furman, R. R., Buggy, J., Loury, D., Hamdy, A., Advani, R.
AMER SOC HEMATOLOGY.2010: 425
- **Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma**
Shustov, A. R., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramachandren, R., Fanale, M. A., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, et al
AMER SOC HEMATOLOGY.2010: 423-24
- **The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase I Studies**
Burger, J. A., O'Brien, S., Fowler, N., Advani, R., Sharman, J., Furman, R. R., Izumi, R., Buggy, J., Loury, D., Hamdy, A., Byrd, J. C., Blum, K. A.
AMER SOC HEMATOLOGY.2010: 32
- **Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase I Study In Patients with CD20-Positive Lymphoid Malignancies** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Kahl, B., Roberts, A. W., Seymour, J. F., Advani, R. H., Persky, D. O., Yang, J., Cui, Y., Busman, T., Krivoshik, A., Enschede, S., Humerickhouse, R.
AMER SOC HEMATOLOGY.2010: 1608-
- **Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., Advani, R., Natkunam, Y., Levy, R.
AMER SOC HEMATOLOGY.2010: 1291-92
- **In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J., Czerwinski, D., Xing, L., Morales, A., Ai, W., Abdulla, F., Navi, D., Tibshirani, R. J., Advani, R., Natkunam, et al
AMER SOC HEMATOLOGY.2010: 130-30
- **A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)**
Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Gospodarowicz, M., Advani, R., Kahl, B., Friedberg, et al
AMER SOC HEMATOLOGY.2010: 185
- **Randomized Phase III Trial Comparing ABVD plus Radiotherapy and the Stanford V.Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A-Subset Analysis of the US Intergroup Trial E2496**
Advani, R., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, S., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Gordon, L. I., Kahl, B., Friedberg, et al
AMER SOC HEMATOLOGY.2010: 185-86
- **A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., Liedtke, M., Mitchell, B. S., Medeiros, B. C.
AMER SOC HEMATOLOGY.2010: 1347-47
- **In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study** *JOURNAL OF CLINICAL ONCOLOGY*
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., Wapnir, I., Tibshirani, R. J., Levy, et al
2010; 28 (28): 4324-4332

- **Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for F-18 FDG PET/CT Surveillance?** *23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)*
Lagaru, A., Maeda, L. S., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., Gambhir, S. S., Advani, R. H.
SPRINGER.2010: S212-S213
- **A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY**
Fowler, N., Sharman, J., Smith, S., Pollyea, D., Boyd, T., Grant, B., Kathryn, K., Buggy, J., Louny, D., Hamdy, A., Advani, R.
FERRATA STORTI FOUNDATION.2010: 371
- **PHASE 1 STUDY OF NAVITOCCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES**
Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., Busman, T., Krivoshik, A., Enschede, S., Humerickhouse, R.
FERRATA STORTI FOUNDATION.2010: 371
- **PHASE 1 STUDY OF NAVITOCCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES** *15th Annual Meeting of the European-Hematology-Association*
Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., Busman, T., Krivoshik, A., Enschede, S., Humerickhouse, R.
FERRATA STORTI FOUNDATION.2010: 371-371
- **A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY**
Fowler, N., Sharman, J., Smith, S., Pollyea, D., Boyd, T., Grant, B., Kathryn, K., Buggy, J., Louny, D., Hamdy, A., Advani, R.
FERRATA STORTI FOUNDATION.2010: 371
- **Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience**
Maeda, L. S., Hoppe, R. T., Warnke, R. A., Natkunam, Y., Rosenberg, S. A., Homing, S. J., Advani, R.
AMER SOC CLINICAL ONCOLOGY.2010
- **Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study**
Advani, R., Sharman, J. P., Smith, S. M., Pollyea, D. A., Boyd, T. E., Grant, B. W., Kolibaba, K. S., Buggy, J. J., Hamdy, A., Fowler, N. H.
AMER SOC CLINICAL ONCOLOGY.2010
- **Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial**
Foss, F. M., Sjak-Shie, N. N., Goy, A., Advani, R., Jacobsen, E. D.
AMER SOC CLINICAL ONCOLOGY.2010
- **ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma** *CURRENT PROBLEMS IN CANCER*
Ng, A., Constine, L. S., Advani, R., Das, P., Flowers, C., Friedberg, J., Hodgson, D. C., Schwartz, C. L., Wilder, R. B., Wilson, L. D., Yunes, M. J.
2010; 34 (3): 211-227
- **Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules** *CLINICAL CANCER RESEARCH*
Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., Wakelee, H. A., Hoch, U., Silverman, J. A., Havrilla, N. A., Berman, C. J., Fox, J. A., Allen, R. S., Adelman, et al
2010; 16 (7): 2167-2175
- **Non-Hodgkin's Lymphomas** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., Gordon, L. I., Harris, N. L., Hoppe, et al
2010; 8 (3): 288-334
- **NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., Gordon, L. I., Harris, N. L., Hoppe, et al
2010; 8 (3): 288-334
- **Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study** *BLOOD*
Hornig, S. J., Juweid, M. E., Schoeder, H., Wiseman, G., McMillan, A., Swinnen, L. J., Advani, R., Gascoyne, R., Quon, A.
2010; 115 (4): 775-777

- **Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunotherapy (R-CHOP)** *BRITISH JOURNAL OF HAEMATOLOGY*
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., Horning, S., Sehn, L. H., Farinha, P., Briones, J., Lossos, I. S., Gascoyne, R. D., Natkunam, et al
2010; 148 (2): 235-244
- **Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease** *52nd Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO)*
Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Rosenberg, S. A., Hoppe, R. T., Quon, A., Graves, E. E., Loo, B. W., Tran, P. T.
ELSEVIER SCIENCE INC.2010: S546-S547
- **Analysis of Breast Cancer Subtypes in Women who Develop Breast Cancer following Mantle Irradiation for Hodgkin's Disease**
Horst, K. C., Hancock, S., Advani, R., Horning, S., Rosenberg, S., Hoppe, R. T.
ELSEVIER SCIENCE INC.2010: S206-S207
- **MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma**
Alencar, A. J., Malumbres, R., Advani, R., Talreja, N., Shyam, R., Briones, J., Natkunam, Y., Gascoyne, R. D., Tibshirani, R., Lossos, I. S.
AMER SOC HEMATOLOGY.2009: 258-59
- **Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.**
Horwitz, S. M., Vose, J. M., Advani, R., Sankhala, K., Padmanabhan, S., Hamlin, P. A., Chen, A., Zain, J. M., Fruchtman, S., O'Connor, O. A.
AMER SOC HEMATOLOGY.2009: 667-68
- **Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma**
Pohlman, B., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Ben-Yehuda, D., Beylot-Barry, M., Hillen, U., Fagerberg, J., Foss, et al
AMER SOC HEMATOLOGY.2009: 379
- **Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.**
Advani, R. H., Hong, F., Ganjoo, K. N., Manola, J. B., Swinnen, L. J., Habermann, T. M., Horning, S. J.
AMER SOC HEMATOLOGY.2009: 667
- **A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Pollyea, D. A., Smith, S., Fowler, N., Boyd, T. E., Smith, A. M., Sirisawad, M., Honigberg, L. A., Hamdy, A., Advani, R.
AMER SOC HEMATOLOGY.2009: 1430-30
- **Role of FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Maeda, L. S., Horning, S. J., Iagaru, A. H., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., Advani, R. H.
AMER SOC HEMATOLOGY.2009: 626-26
- **CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Dornan, D., Burington, B., Yue, P., Shi, X., Advani, R., Yu, N., Lau, J. T., Yu, S., de Vos, S., Ansell, S. M., Forero-Torres, A., Modrusan, Z., Koepfen, et al
AMER SOC HEMATOLOGY.2009: 1065-65
- **The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E., Advani, R., Horning, S. J.
AMER SOC HEMATOLOGY.2009: 663-63
- **The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma** *CURRENT OPINION IN ONCOLOGY*
Maeda, L. S., Advani, R. H.
2009; 21 (5): 397-400
- **Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome** *49th Annual Meeting of the American-Society-of-Hematology*
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., Hoppe, R. T., Kim, Y. H.
AMER MEDICAL ASSOC.2009: 667-74

- **Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP)** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Horning, S. J., Levy, R., Lossos, I. S., Gascoyne, R. D., Natkunam, Y.
AMER SOC CLINICAL ONCOLOGY.2009
- **A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients**
Robert, F., Verschraegen, C., Hurwitz, H., Uronis, H., Advani, R., Chen, A., Taverna, P., Wollman, M., Fox, J., Michelson, G.
AMER SOC CLINICAL ONCOLOGY.2009
- **Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Kohrt, H. E., Advani, R., Hoppe, R., Rosenberg, S., Horning, S., Lee, P. P.
AMER SOC CLINICAL ONCOLOGY.2009
- **A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma**
Burlington, B., Advani, R., Shi, X., Yue, P., Lau, J., Yu, S., Januario, T., de Vos, S., Ansell, S., Forero-Torres, A., Ebens, A., Whiting, N., Dornan, et al
AMER ASSOC CANCER RESEARCH.2009
- **Targeting CD40 in Waldenstrom's Macroglobulinemia** *5th International Workshop on Waldenstroms Macroglobulinemia*
Lee, M., Advani, R.
CIG MEDIA GROUP, LP.2009: 87-89
- **Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment** *LEUKEMIA & LYMPHOMA*
Kohrt, H., Advani, R.
2009; 50 (11): 1773-1784
- **CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas**
Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., Wong, A., Talreja, N., Levy, R., Levy, S., Natkunam, Y.
NATURE PUBLISHING GROUP.2009: 275A
- **CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas** *98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., Wong, A., Talreja, N., Levy, R., Levy, S., Natkunam, Y.
NATURE PUBLISHING GROUP.2009: 275A-275A
- **Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease** *ONCOLOGY RESEARCH*
Kohrt, H., Johannsen, A., Hoppe, R., Horning, S. J., Rosenberg, S. A., Advani, R., Lee, P. P.
2009; 18 (5-6): 287-292
- **Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., Kim, Y. H.
2008; 59 (6): 953-957
- **Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.** *Clinical advances in hematology & oncology : H&O*
Alizadeh, A. A., Advani, R. H.
2008; 6 (12): 899-909
- **LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study.** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., Bordes, R., Cohen, J., Horning, S., Levy, R., Lossos, I. S., Natkunam, Y.
AMER SOC HEMATOLOGY.2008: 1291-91
- **Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404**
Horning, S. J., Juweid, M. E., Schoder, H., Wiseman, G., McMillan, A., Swinnen, L. J., Advani, R., Gascoyne, R. D., Quon, A.
AMER SOC HEMATOLOGY.2008: 145
- **A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.**
Advani, R., De Vos, S., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., Furman, R. R., Winter, J. N., Kaplan, H., Dornan, D., Whiting, N., Drachman, J., Forero-Torres, et al

AMER SOC HEMATOLOGY.2008: 368

- **A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Horwitz, S. M., Vose, J. M., Advani, R., Sankhala, K., Padmanabhan, S., Hamlin, P. A., Chen, A., Wilroy, S., Zain, J. M., Wright, D., Weissbrot, H., Hohenstein, M., Cagnoni, et al
AMER SOC HEMATOLOGY.2008: 557-57
- **Phase I trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients**
Robert, F., Hurwitz, H., Uronis, H., Verschraegen, C., Advani, R., Chen, A., Messerschmidt, G. L., Havrilla, N., Taverna, P., Evanchik, M.
PERGAMON-ELSEVIER SCIENCE LTD.2008: 91-92
- **Hodgkin disease/lymphoma.** *Journal of the National Comprehensive Cancer Network*
Hoppe, R. T., Advani, R. H., Ambinder, R. F., Bierman, P. J., Bloomfield, C. D., Blum, K., Dabaja, B., Djulbegovic, B., Forero, A., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Hudson, M. M., Kaminski, et al
2008; 6 (6): 594-622
- **Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP** *BLOOD*
Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., Briones, J., Advani, R., Connors, J. M., Byrne, G. E., Levy, R., Gascoyne, R. D., Lossos, et al
2008; 111 (12): 5509-5514
- **Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676]** *10th International Conference on Malignant Lymphoma*
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Advani, R., Horning, S. J., Hoppe, R. T., Levy, R.
OXFORD UNIV PRESS.2008: 158-158
- **SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin lymphoma: Final results of a phase I dose-escalation study**
Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Harrop, K., Whiting, N. C., Drachman, J. G.
OXFORD UNIV PRESS.2008: 115
- **Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003** *10th International Conference on Malignant Lymphoma*
Tan, D., Rosenberg, S. A., Lavori, P., Levy, R., Hoppe, R., Warnke, R., Advani, R., Natkunam, Y., Yuen, A., Horning, S. J.
OXFORD UNIV PRESS.2008: 111-112
- **Attitudes and beliefs towards survivorship issues in Hodgkin's disease (HD). Results of focus group discussions with patients treated at stanford university** *10th International Conference on Malignant Lymphoma*
Advani, R., Rosenberg, S., Talreja, N., Hoppe, R., Horning, S.
OXFORD UNIV PRESS.2008: 137-137
- **Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909**
Brody, J., Ai, W. Z., Czerwinski, D., Advani, R., Horning, S. J., Ganjoo, K. N., Levy, R.
AMER SOC CLINICAL ONCOLOGY.2008
- **Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003**
Tan, D., Rosenberg, S. A., Lavori, P., Sigal, B. M., Levy, R., Hoppe, R. T., Warnke, R., Advani, R., Natkunam, Y., Plevritis, S. K., Horning, S. J.
AMER SOC CLINICAL ONCOLOGY.2008
- **Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.** *Journal of the National Comprehensive Cancer Network*
Chen, A. I., Advani, R. H.
2008; 6 (4): 428-435
- **Non-Hodgkin's lymphomas.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Advani, R. H., Byrd, J. C., Czuczman, M. S., Damon, L. E., Duvic, M., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., Gordon, L. I., Harris, N. L., Hoppe, et al
2008; 6 (4): 356-421
- **Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial** *49th Annual Meeting of the American-Society-of-Hematology*
Foss, F., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M., Komrokji, R., Pendergrass, K., Bolejack, V., Watts, K., Acosta, M.

AMER SOC HEMATOLOGY.2007: 1011A–1011A

- **Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD)**
Horning, S. J., Bartlett, N. L., Breslin, S., Advani, R. H., Hoppe, R. T., Ekstrand, B. C., Lucas, J. B.
AMER SOC HEMATOLOGY.2007: 198A
- **Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study** *49th Annual Meeting of the American-Society-of-Hematology*
Advani, R., Hymes, K., Pohlman, B., Jacobsen, E., McDonnell, J., Belt, R., LERNER, A., Kim, Y., MUNDIS, R., MANSFIELD, T., Buhl-Jensen, P., Ooi, C. E., Duvic, et al
AMER SOC HEMATOLOGY.2007: 1012A–1012A
- **Stage I/II Hodgkin's disease: Comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience**
Advani, R. H., Hoppe, R. T., Rosenberg, S. A., Horning, S. J.
AMER SOC HEMATOLOGY.2007: 685A–685A
- **Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499** *49th Annual Meeting of the American-Society-of-Hematology*
Smith, M. R., Zhang, L., Gordon, L. I., Foran, J., Kahl, B., Gascoyne, R. D., Advani, R., Paietta, E., Weller, E., Horning, S. J.
AMER SOC HEMATOLOGY.2007: 121A–121A
- **Survival in follicular lymphoma: The Stanford experience, 1960-2003.** *49th Annual Meeting of the American-Society-of-Hematology*
Tan, D., Rosenberg, S. A., Levy, R., Lavori, P., Tibshirani, R., Hoppe, R. T., Warnke, R., Advani, R., Natkunam, Y., Yuen, A., Horning, S. J.
AMER SOC HEMATOLOGY.2007: 1005A–1005A
- **Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome** *49th Annual Meeting of the American-Society-of-Hematology*
Woo, D., Jones, C., Vanoli-Storz, M., Kohler, S., Reddy, S., Advani, R., Hoppe, R., Kim, Y.
AMER SOC HEMATOLOGY.2007: 1045A–1045A
- **Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience** *7th International Symposium on Hodgkins Lymphoma*
Advani, R. H., Hoppe, R. T., Rosenberg, S. A., Horning, S. J.
FERRATA STORTI FOUNDATION.2007: 27–27
- **A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy** *7th International Symposium on Hodgkins Lymphoma*
Horning, S. J., Hoppe, R. T., Advani, R. H., Breslin, S., McCormick, E., Allen, J., Hancock, S. L., Rosenberg, S. A.
FERRATA STORTI FOUNDATION.2007: 53–53
- **Intra-CSF rituximab for lymphomatous meningitis - Reply** *JOURNAL OF CLINICAL ONCOLOGY*
Rubenstein, J., Abrey, L., Advani, R., Shuman, M., Tsai, T., O'Brien, J.
2007; 25 (28): 4509-4511
- **Non-Hodgkin lymphoma of the breast** *CANCER*
Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., Horning, S.
2007; 110 (1): 25-30
- **Confirmation of the prognostic value of the EORTC/WHO classification of primary cutaneous B-cell lymphoma in the United States: The Stanford University experience**
Reddy, S. A., Kim, Y. H., Advani, R. H., Hoppe, R. T.
AMER SOC CLINICAL ONCOLOGY.2007
- **A prospective trial of involved field radiation (IFRT) plus chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy**
Horning, S. J., Hoppe, R. T., Advani, R. H., Breslin, S., Allen, J., Hancock, S. L., Rosenberg, S. A.
AMER SOC CLINICAL ONCOLOGY.2007
- **Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248** *CLINICAL CANCER RESEARCH*
Treon, S. P., Hunter, Z. R., Matous, J., Joyce, R. M., Mannion, B., Advani, R., Cook, D., Songer, J., Hill, J., Kaden, B. R., Sharon, D., Steiss, R., Leleu, et al

2007; 13 (11): 3320-3325

- **A phase II study of derdlekun diftiox (Ontak (R)) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: Interim analysis.**
Foss, F. M., Sjak-Shie, N., Goy, A., Advani, R., Jacobsen, E., Acosta, M.
AMER SOC HEMATOLOGY.2006: 696A-697A
- **SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study.**
Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Shankles, B., Harrop, K., Drachman, J. G.
AMER SOC HEMATOLOGY.2006: 209A
- **Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499).** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Smith, M. R., Chen, H., Gordon, L., Foran, J., Kahl, B., Advani, R., Gascoyne, R. D., Weller, E., Horning, S. J.
AMER SOC CLINICAL ONCOLOGY.2006: 422S-422S
- **SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies.**
Hurwitz, H., Gordon, M., Advani, R., Ebbinghaus, S., Mendelson, D., Wakelee, H., Hoch, U., Silverman, J., Havrilla, N., Adelman, D.
AMER SOC CLINICAL ONCOLOGY.2006: 136S
- **A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study.**
Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Harrop, K., Drachman, J. G., Advani, R.
AMER SOC CLINICAL ONCOLOGY.2006: 430S
- **Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University.** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R. H., Hoppe, R. T., Rosenberg, S. A., Horning, S. J.
AMER SOC CLINICAL ONCOLOGY.2006: 426S-426S
- **Treatment of mantle cell lymphoma: Current approach and future directions** *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*
Brody, J., Advani, R.
2006; 58 (3): 257-265
- **Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography** *65th Annual Meeting of the Society-for-Investigative-Dermatology*
Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., Dick, S., Chow, S., Advani, R., Warnke, R., Kohler, S., Hoppe, R. T., Kim, Y. H.
AMER MEDICAL ASSOC.2006: 577-84
- **A phase I trial of weekly SNS-595 in patients (PTS) with refractory cancer**
Ebbinghaus, S., Gordon, M., Advani, R., Hurwitz, H., Mendelson, D., Wakelee, H., Hoch, U., Silverman, J., Havrilla, N., Adelman, D.
AMER ASSOC CANCER RESEARCH.2006
- **Management of advanced stage Hodgkin lymphoma.** *Journal of the National Comprehensive Cancer Network*
Advani, R., Ai, W. Z., Horning, S. J.
2006; 4 (3): 241-247
- **Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Zelenetz, A. D., Advani, R. H., Buadi, F., Cabanillas, F., Caligiuri, M. A., Czuczman, M. S., Damon, L. E., Fayad, L., Flinn, I. W., Forero, A., Glenn, M. J., Gockerman, J. P., Gordon, et al
2006; 4 (3): 258-310
- **Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Hoppe, R. T., Advani, R. H., Bierman, P. J., Bloomfield, C. D., Buadi, F., Djulgegovic, B., Forero, A., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Kaminski, M. S., Love, G., Maloney, D. G., Mauch, et al
2006; 4 (3): 210-230
- **Phase I trial of SNS-595 in patients (pts) with advanced malignancies.**
Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., Hoch, U., Silverman, J., Havrilla, N., Adelman, D.
AMER ASSOC CANCER RESEARCH.2005: 9056S

- **A phase I trial of liposomal doxorubicin, paclitaxel and valsopodar (PSC-833), an inhibitor of multidrug resistance** *ANNALS OF ONCOLOGY*
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., Sikic, B. I.
2005; 16 (12): 1968-1973
- **Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL).** *47th Annual Meeting of the American-Society-of-Hematology*
Kahl, B. S., Advani, R., Kay, N., Lossos, I. S., Evens, A., Gordon, L., MILLER, R. A., Phan, S. C.
AMER SOC HEMATOLOGY.2005: 269B–270B
- **A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma.**
Advani, R. H., Furman, R. R., Rosenblatt, J. D., Younes, A., Forero-Torres, A., Harrop, K. L., Baumgartner, K. T., McDonald, M., Drachman, J. G.
AMER SOC HEMATOLOGY.2005: 433A
- **Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma.** *47th Annual Meeting of the American-Society-of-Hematology*
Molina, A. M., Advani, R., Reddy, S., Hoppe, R., Friedberg, J. W., Sadan, S., Myskowski, P., Kim, Y. H., Horwitz, S. M.
AMER SOC HEMATOLOGY.2005: 934A–934A
- **Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248.** *47th Annual Meeting of the American-Society-of-Hematology*
Treon, S., Hunter, Z. R., Matous, J., Badros, A., Joyce, R. M., Mannion, B., Advani, R., Cook, D., Songer, J., Hill, J., Kaden, B. R., Sharon, D., Steiss, et al
AMER SOC HEMATOLOGY.2005: 147A–147A
- **Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience.** *47th Annual Meeting of the American-Society-of-Hematology*
Advani, R., Maeda, L., Hoppe, R. T., Breslin, S., Rosenberg, S. A., Baer, D., Mason, J., Horning, S. J.
AMER SOC HEMATOLOGY.2005: 548A–548A
- **A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J. T., Kwoh, T. J., DORR, F. A., Sikic, B. I.
SPRINGER.2005: 467–77
- **PET status after Stanford V chemotherapy predicts outcome in Hodgkins disease** *9th International Conference on Malignant Lymphoma*
Advani, R., Maeda, L., Lavori, P., Hoppe, R., Breslin, S., Rosenberg, S., Horning, S.
OXFORD UNIV PRESS.2005: 121–121
- **Phase I trial of SNS-595 in patients with advanced malignancies.**
Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., Hoch, U., Silverman, J., Havrilla, N., Adelman, D.
AMER SOC CLINICAL ONCOLOGY.2005: 159S
- **A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies** *41st Annual Meeting of the American-Society-of-Clinical-Oncology*
Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzgerald, A. M., Sikic, B.
AMER SOC CLINICAL ONCOLOGY.2005: 234S–234S
- **A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer.** *Investigational New Drugs*,
Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI.
2005; In Press
- **Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients.** *46th Annual Meeting of the American-Society-of-Hematology*
Horning, S. J., Hoppe, R. T., Advani, R., Warnke, R., Baer, D., Mason, J., Rosenberg, S. A.
AMER SOC HEMATOLOGY.2004: 92A–92A
- **Marked improvement in staging accuracy in mycosis fungoides/Sezary syndrome using integrated positron emission tomography and computed tomography (PET/CT)**
Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Dick, S. E., Chow, S., Advani, R., Warnke, R. A., Kohler, S., Hoppe, R. T., Kim, Y. H.
AMER SOC HEMATOLOGY.2004: 854A–855A
- **A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*

Fishe, G. A., Kuo, T., Cho, C. D., Halsey, J., Jambalos, C. N., Schwartz, E. J., Robert, R. V., Advani, R. H., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2004: 248S–248S

- **Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)** *JOURNAL OF CLINICAL ONCOLOGY*
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B., Chin, D. L., Dewald, G., Paietta, E., Bennett, J. M., Rowe, et al
2004; 22 (6): 1078-1086
- **A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.** *AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics*
Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., Advani, R. H., Wakelee, H. A., Lum, B. L., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2003: 6103S–6103S
- **Treatment of angioimmunoblastic T-cell lymphoma (AILD) with cyclosporine.**
Advani, R., Horwitz, S., Harandi, A., Lee, M., Noy, A., Zelenetz, A. D., Horning, S. J.
AMER SOC HEMATOLOGY.2003: 180A
- **Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies** *CLINICAL CANCER RESEARCH*
Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., Gollerkeri, A., Sikic, B. I.
2003; 9 (14): 5187-5194
- **A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies** *14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics*
Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., Lum, B. L., Sikic, B. I.
ELSEVIER SCI LTD.2002: S63–S63
- **Functional characterization of Rab14 GTPase and its role in membrane trafficking and vesicular transport**
Junutula, Advani, R. J., Peden, A. A., de Maziere, A., Klumperman, J., Scheller, R. H.
AMER SOC CELL BIOLOGY.2002: 227A–228A
- **The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin.**
Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey, J., Sikic, B. I.
NATURE PUBLISHING GROUP.2002: P48–P48
- **Phase II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer: Updated survival and time to progression data.**
Yuen, A., Halsey, J., Fisher, G., Advani, R., Moore, M., Saleh, M., Ritch, P., Harker, G., Ahmed, F., Jones, C., Polikoff, J., Keiser, W., Kwoh, et al
AMER ASSOC CANCER RESEARCH.2001: 3681S
- **A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance** *34th Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2001: 1221–29
- **Enhanced bioavailability of oral paclitaxel by valspodar (PSC 833), an inhibitor of small bowel P-glycoprotein and cytochrome P450.**
Sikic, B. I., Advani, R., Fisher, G. A., Halsey, J., Cohen, P., Lum, B. L.
AMER ASSOC CANCER RESEARCH.2000: 4580S
- **Phase I/II trial of ISIS3521, an antisense inhibitor of PKC alpha, with carboplatin and paclitaxel in non-small cell lung cancer.**
Yuen, A., Halsey, J., Lum, B., Fisher, G., Advani, R., Geary, R., Kwoh, T. J., Holmlund, J. T., Dorr, A., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2000: 4572S
- **A phase I trial of doxil, paclitaxel and valspodar (PSC 833).**
Advani, R., Fisher, G., Lum, B., Halsey, J., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2000: 4504S
- **Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995).**
Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., Lee, S. J., Lum, B., Sikic, B. I., Paietta, E., Bennett, J., Rowe, J. M.
AMER SOC HEMATOLOGY.1999: 383A–383A

- **Schedule and concentration dependent increase of coagulation times and complement split products in phase I/II trials of an antisense oligonucleotide targeted to protein kinase C-alpha (ISIS 3521/ISI641A).**

Advani, R., Lum, B. L., Fisher, G. A., Grant, P., Halsey, J., Yuen, A., Holmlund, J. T., Kwoh, T. J., Dorr, A., Geary, R., Sikic, B. I.
AMER SOC HEMATOLOGY.1999: 94B

- **A phase I trial of ISIS 3521 (ISI641A), an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with cancer.**

Yuen, A., Sikic, B. I., Advani, R., Fisher, G., Halsey, J., Lum, B., Geary, R., Kwoh, T. J., Holmlund, J. T., Dorr, A.
AMER ASSOC CANCER RESEARCH.1999: 3846S-3847S

- **Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). *Blood***

Advani R, Saba HI, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Sikic BI, Davis E, Paietta E, Litchman M, Greenberg P.
1999; 93: 787-95

- **Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC).**

Advani, R., Saba, H. I., Tallman, M., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Sikic, B. I., Davis, E., Paietta, E., Litchman, et al
W B SAUNDERS CO.1997: 2260

- **Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC)**

Advani, R., Saba, H., Rowe, J. M., Tallman, M., Wiernik, P., Ramek, J., Dugan, K., Litchman, M., Dorr, R., Lum, B., Sikic, B., Davis, E., Paietta, et al
W B SAUNDERS CO.1996: 847